Counterbalancing Cancer Growth: Harnessing Intrinsic Regulatory Pathways for Novel Anti-oncogenic Strategies by Ma, B. (Buyun)
  
 
 
 
 
 
 
 
 
 
Counterbalancing Cancer Growth: Harnessing 
Intrinsic Regulatory Pathways for Novel Anti-
oncogenic Strategies 
 
 
 
 
 
 
 
 
 
 
Buyun Ma 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The studies presented in this thesis were performed at the Laboratory of Gastroenterology 
and Hepatology, Erasmus MC-University Medical Center Rotterdam, the Netherlands. 
 
The research was funded by:  
Netherlands Organization for Scientific Research (NWO); Dutch Digestive Foundation 
(MLDS); Daniel den Hoed Foundation; China Scholarship Council 
 
© Copyright by Buyun Ma. All righs reserved. 
No part of the thesis may be reproduced or transmitted, in any form, by any means, without 
express written permission of the author. 
 
Cover design and layout: Optima Grafische Communicatie 
 
Printed by: Optima Grafische Communicatie 
 
ISBN: 978-94-6361-319-4 
  
 
Counterbalancing Cancer Growth: Harnessing 
Intrinsic Regulatory Pathways for Novel Anti-
oncogenic Strategies 
 
 
Regulatoire Circuits in Kanker: verschuiving van het 
evenwicht 
 
 
Thesis 
 
to obtain the degree of Doctor from the 
Erasmus University Rotterdam 
by command of the  
rector magnificus 
Prof.dr. R.C.M.E. Engels 
and in accordance with the decision of the Doctorate Board 
The public defense shall be held on  
 
Wednesday 11th September 2019 at 13:30 
 
by 
 
Buyun Ma 
born in Dongyang, Zhejiang Province, China 
                        
  
Doctoral Committee 
Promoter: 
Prof.dr. M. P. Peppelenbosch 
 
Inner Committee: 
Prof.dr. H.J. Metselaar 
Prof.dr. J.C.H. Hardwick 
Prof.dr. R.A. de Man 
 
Copromoter: 
Dr. Q. Pan 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cover: 
Picture is from iStock (http://www.istockphoto.com/) and designed by Optima Grafische 
Communicatie. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CONTENTS 
 
Chapter 1 General introduction and outline of the thesis 9 
Chapter 2 Inhibiting experimental and clinical hepatocellular carcinoma by 
mycophenolic acid involves formation of cytoplasmic rods and rings 
(Adapted from Transplantation. 2019 May;103(5):929-937 and Liver Int. 2017 
Nov;37(11):1742-1743) 
23 
Chapter 3 The two isoforms of IMPDH distinctively associate with patient outcome and 
exert dichotomic functions in hepatocellular carcinoma  
(submitted) 
49 
Chapter 4  Dichotomal functions of phosphorylated and unphosphorylated STAT1 in 
hepatocellular carcinoma 
(J Mol Med (Berl). 2019 Jan; 97(1):77-88.) 
85 
Chapter 5 Human intestinal and liver stem cells counteract telomerase-targeted 
anticancer therapy  
(submitted) 
117 
Chapter 6 Genetically engineered bacteria for treating human disease  
(Trends in Pharmacological Sciences. 2017 Sep; 38(9):763-764) 
155 
Chapter 7 Summary and discussion 163 
Chapter 8 Dutch summary 173 
Appendix    
Acknowledgements 181 
Publications 185 
PhD Portfolio 187 
Curriculum Vitae 189 
 
 
 
 
 
  
  
 
Chapter 1 
 
General introduction and  
outline of the thesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
General introduction 
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1. Cancer 
Cancer, often a devastating disease provoking untold human misery, has been recognized as 
a separate pathological condition for almost as long as written records exist, already being 
described in ancient Egyptian texts (e.g. in the almost 5000 year old Edwin Smith Papyrus).  
Its current name derives from a text attributed to Hippocrates in which non-ulcer forming 
and ulcer-forming tumors were compared to crab or crayfish (the ancient Greek word being 
καρκίνος)1. Now, cancer has become the second leading cause of death globally2. Generally 
speaking, cancer is a group of diseases characterized by uncontrolled cell growth and the 
ability of the cell spreading to other parts of the body3. The damage to the body is manifold 
but also physical through space occupation. Concomitant with the advance in understanding 
cancer, it has become clear that cancer is mainly a genetic disease with alterations in cancer 
cell DNA, driving the pathological process. Consequently, external agents (physical, chemical 
and biological carcinogens) and internal events which can disturb/interact with human 
genetic factors are the most important causes of cancer. It is hoped that further 
understanding of the cancer process will open novel avenues for rational treatment of 
cancer. The current thesis hopes to contribute in this respect. 
Genetic changes driving cancer generally involve gain-of-function mutations in proto-
oncogenes and loss of function mutations in tumor suppressor genes. The consequences of 
specific mutation can be highly context specific: while the transcription factor SMAD4 usually 
acts as a tumor suppressor4, in the context of liver cancer it acts like an oncogene5. Multiple 
successive alterations in the genomes create genetic diversity and underlie the 
transformation of normal cells to cancer cells. The cancer process is complicated and 
different hallmarks have been proposed to understand cancer. These hallmarks include 
continuing proliferative signaling, evasion of growth suppressive signaling, resisting 
(programmed) cell death, replicative immortality, induction of angiogenesis, a capacity for 
invasion and metastasis, deregulated cellular energy metabolism and avoiding immune 
destruction6. Better understanding the interactions between the different elements of the 
cancer process will foster better comprehension of efficacy of treatment and allow better 
therapeutic strategies. 
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2. Liver cancer 
Liver cancer is the cancer that starts in liver and includes hepatocellular carcinoma (HCC), 
cholangiocarcinoma and hepatoblastoma. It is a major health problem, with more than 
850000 new cases annually and it is the second leading cause of cancer-related death 
worldwide7. As the most common cancer of the liver cancer, HCC accounts for approximately 
90% of liver cancer cases8. The etiology of HCC is reasonably well defined and development 
of this disease is linked to hepatitis virus (HBV, HCV) infection, metabolic syndrome and 
alcohol abuse9. Development of HCC is a multistep process, with most of the cases occurring 
in the context of cirrhosis. With the advent of high-performance genomic analyses, 
knowledge on the molecular pathogenesis of HCC has remarkably increased over the past 
decade. Accordingly, various key mutations and pathways have been identified and these 
include processes involved telomere maintenance, activation of Wnt signaling, inactivation 
of p53, chromatin remodeling, stimulation of the Ras and PI3K pathways as well as the 
oxidative stress pathway7. This increased insight has not yet translated in improved 
therapeutic strategies, with surgical resection (often in conjunction with liver 
transplantation) remaining the only curative option, whereas oral multiple kinase inhibitors 
such as sorafenib, turn out with moderate clinical benefit10. In addition, immunotherapy has 
now emerged as an alternative treatment approach that has been successful in many cancer 
types. Promising response rate and survival durations in HCC patients have also been 
observed with the use of immune-checkpoint inhibitors11. Nivolumab, a monoclonal 
antibody targeting programmed cell death protein 1 (PD-1), has been granted accelerated 
approval by the FDA as a second line treatment and is currently being tested against 
sorafenib in a phase III trial in the first line setting (NCT02576509)12. The paucity of options 
in this respect urgently calls for further studies in this respect and much of the work in this 
thesis is a reaction to that need. Especially interesting in this respect is that patients 
receiving orthotopic liver transplantation for HCC are being treated by immunosuppressive 
medication which may interact with the cancer process, especially as many of the 
medications involved are cell cycle-inhibiting compounds interfering with nucleotide biology. 
Further understanding of the biology of the interaction of such medication with the cancer 
may thus lead to improved therapy, in this thesis I aim to explore this angle. 
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3. Colorectal cancer 
Colorectal cancer (CRC), which arises either from the colon or the rectum, is the third most 
common cancer. Risk factors for CRC are mainly aging and various lifestyle factors (meat 
consumption, sedentary life style, absence of NSAID use etc.), with a small population of 
cases due to genetic disorders that confer strongly increase risk for CRC developent13. 
Although on a molecular level the group of pathologies clustered under the denominator 
CRC is quite heterogeneous, three main molecular mechanisms emerge as principal 
mediator of CRC development, in casu chromosomal instability (CIN), CpG island methylator 
phenotype (CIMP), and the microsatellite instability (MSI)14. Population-wide screening 
efforts should be instrumental in reducing CRC burden, but if these could be combined with 
other efforts aimed at reducing CRC mortality, efficacy might be increased. In this thesis I 
shall explore both mechanistic aspects of CRC as well as novel models for prevention of this 
disease. 
4. Tumor microenvironment and immunology 
Remodeling of the microenvironment is a hallmark in the pathogenesis of cancer15. Co-
evolution of (presumptive) tumor cells with microenvironment may create a selective 
landscape that drives sequentially tumor initiation, progression and metastasis. In important 
factor to consider in this respect is the immune system. As immune surveillance is important 
for the eradicating formation and progression of cancer, defect of the immune system, 
recognized as immunosuppression, is validated in increasing certain cancers16. Notably, 
immunosuppression is found in majority of virus-induced cancers. Studying the tumor 
microenvironment, including the different cell types and the crosstalk between it, would be 
expected to help understanding the biology of cancer. 
STAT1 and IFN signaling pathways 
Interferons (IFNs) are pleiotropic cytokines that protect against diseases by direct effects on 
target cells (cell autonomous effects) and by activating immune responses. There are three 
major types of IFNs, including type I IFNs (13 subtypes of IFNα, plus IFNβ, IFNε, IFNκ and 
IFNω), type II IFNs (IFNγ), and type III IFNs (IFNλ1, IFNλ2, IFNλ3, IFNλ4)17. Among them, type I 
IFNs are especially prominent and expressed by various cell types where they exert their 
effects in an autocrine or paracrine manner. In comparison, type II and type III IFNs are more 
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restricted, both with respect to spectrum of cells that express these cytokines and the 
diversity in reactions they elicit in the body. IFN-based therapy has been developed and 
employed for cancer treatment now for decades. All IFNs have the anti-tumor function by 
directly acting on tumor cells or by activating the immune cells17. Besides potential action on 
tumor cells, IFNs are important for defense of viral infection and elimination. Thus, IFNs 
treatment also is important for preventing cancer by limiting progression from simple 
infection to virus-induced cancer18. 
Virus infection including HBV and HCV, which often lead to the chronic viral hepatitis, 
are the major risk factors for HCC. IFNs, especially type I IFNs, have been well-studied and 
used in clinic for prevention and treatment of viral hepatitis-related HCC7. By binding to their 
cognate receptors on responding cells, type I IFNs signal through the key class of 
transcription factors, signal transducers and activators of transcription (STATs), and provoke 
transcription and expression of IFN-regulated genes (IRGs). STAT1 is an important member 
of the STAT family and form homodimers or heterodimers with other STATs upon IFN 
stimulation19, 20. Studies in different types of tumors have demonstrated that STAT1 function 
in tumor progression is pleiotropic, some of its effects being beneficial and other detrimental 
with respect to final outcome of disease. Despite the conventional view that 
phosphorylation of STAT1 is absolutely required for the inducing expression of downstream 
genes, an increasing body of evidence is emerging that demonstrates that unphosphorylated 
STAT1 (u-STAT1) also functions as a transcription factor, even in the absence of IFN 
stimulation21. A different subset of genes was found to be regulated by p-STAT1 and u-
STAT1, which may relate to the variability in effects seen with regard to the role of STAT1 in 
tumor progression. ISGs selectively controlled by u-STAT1, especially STAT1 itself, are 
upregulated in patients after radio- and chemotherapy and this is postulated to contribute 
to therapy resistance22. Despite the previous studies showing that STAT1 functions as a 
tumor suppressor in HCC, exact function of p-STAT1 and u-STAT1 remains largely unknown 
and in this thesis endeavor to obtain better clarity as the exact functionality of STAT1 in the 
liver cancer process. 
5. Cancer metabolism 
Uncontrolled cell proliferation is a key characteristic of cancer cells and importantly is 
associated with reprogramming of cellular metabolism in which the main source of ATP 
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production becomes aerobic glycolysis. Why tumor cells rely on glycolysis even in the 
presence of sufficient oxygen to sustain oxidative phosphorylation remains largely obscure 
but it may well be required to fuel cell growth and division. This so-called “Warburg effect” 
has been subject to an intense research effort and has even labeled as the Achilles heel of 
cancer metabolism23. It is evident that the diverse reprogramming of metabolic activities, 
the corresponding genetic alterations (e.g. genes of metabolic enzymes), may hold promise 
for better therapy. Defining genes and pathways and understanding the specificity of 
metabolic preferences and abilities will provide new insight into cancer biology and benefit 
the clinical patients and also in this aspect of cancer biology I aim to make contributions with 
this thesis. 
Role of IMPDH in cancer progression 
Inosine monophosphate dehydrogenase (IMPDH) is a metabolic enzyme responsible for 
biosynthesis of purine nucleotides, and hence is required for DNA and RNA synthesis. It 
catalyzes the nicotinamide-adenine dinucleotide (NAD+)-dependent oxidation of IMP to 
XMP24. Inhibition of IMPDH results in reduction of cytoplasmic guanine nucleotide pools and 
also the adenylate pools. Being a rate-limiting enzyme of guanosine nucleotide synthesis, 
IMPDH plays a multifaceted, almost kaleidoscopic, role in cell growth and differentiation. 
Interruption of DNA and RNA synthesis results in rapid cell growth arrest25. Human IMPDH 
includes two isoforms, IMPDH1 and IMPDH2, with 84% sequence identity and similar 
properties. To date, the available evidence suggests that IMPDH1 is constitutively expressed 
in most cells, while IMPDH2 is subject to dynamic regulation and its upregulation associated 
with malignant transformation26. Furthermore, IMPDH has been identified as the target of 
mycophenolate mofetil (MMF), an immunosuppressant widely used in organ transplantation 
including for HCC-related liver transplant recipients27. Thus, IMPDH is a potential drugable 
target in disease. As the most prominent metabolic organ in human body, the liver contains 
highly active cells. Thus, based on the considerations spelled-out above I speculate that 
tumor transformation in the liver would be tightly associate with the metabolic 
reprogramming, especially the changes of the metabolic enzymes and that these enzymes 
and especially IMPDH is a potential target here. Thus in this thesis I aim to explore this 
notion and also to obtain better insight of what effect of purine metabolism inhibitors on 
liver cell biology might be.  
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6. Cancer therapy 
HCC is divided into five prognostic subclasses, based on the Barcelona Clinic Liver Cancer 
(BCLC) staging classification. This staging system is also used to select treatment, specific 
therapies offered to patients for individual stage. The treatment involved are mainly limited 
to  surgical resection, liver transplantation, radiofrequency ablation, chemoembolization and 
the multi-kinase inhibitor sorafenib, while recently some patients are also receiving immune-
checkpoint inhibitor therapy. Despite improvement in surveillance programs, which aim at 
early diagnosis, many patients have an initial diagnosis of advanced HCC and are considered 
to be non-curative and display a median overall survival of 1 year10. Thus, there is clear 
therapeutic need with respect to the patients involved. For CRC, colon cancer and rectal 
cancer are these days treated as separate entities and require different approaches 
depending on tumor stage. Surgery is the mainstay of treatment for patients with non-
metastasized CRC and has considerable therapeutic success28. Neoadjuvant treatment is 
recommended for intermediate-stage and advanced-stage rectal cancer but not for colon 
cancer. Adjuvant treatment is recommended for both types of CRC and displays substantial 
clinical benefit. For patients diagnosed with advanced metastasized CRC, chemotherapy 
combinations and targeted therapies have been used and improved the overall survival of 
the patients, but remains depressingly lethal13. The lack of satisfactory treatment options for 
inoperable HCC and CRC requires development of novel therapies. Increased insight into the 
biology of cancer will prove the way forward here.  
Telomerase targeted strategies for cancer therapy 
A potential target for improved therapy that will receive special attention in the work 
described in this thesis is telomerase. Telomerase counteracts DNA loss during cell 
proliferation by adding a species-dependent telomere repeat sequence to the 3' end of the 
telomeres of the chromosomes. Without telomerase activity, chromosomes shorten during 
subsequent cell divisions and become finally incompatible with sustaining tumor cell biology. 
Accordingly, telomerase is expressed in around 90 % of human cancers and is considered an 
attractive therapeutic target for treating oncological disease. Different strategies targeting 
telomerase have been developed. GRN163L (Imetelstat) is the only telomerase inhibitor that 
has entered clinical development, especially for essential thrombocythemia and 
myelofibrosis. However, the efficacy of GRN163 on solid tumors appears limited and this 
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impedes broader applicability29. Alternative approaches are available, however, to target 
telomere length. 6-Thio-deoxyguanosine (6-thio-dG) is an analogue of 6-thioguanine, which 
can interact with telomerase and is preferentially incorporated into telomere. Incorporation 
of the 6-thio-dG subsequently leads to the uncapping of the telomere30. Telomere 
dysfunction caused following uncapping activates the cellular DNA damage response and 
subsequently arrests cell growth. However, targeting telomerase may have undesired effects 
on normal cells with telomerase activity, including some stem cells and progenitor cells31. 
Although only few of such cell populations exist in human body, they are considered 
indispensable for tissue renewal and regeneration. Thus the potential of telomerase 
targeting in the body requires further investigation.  
Genetic modified bacteria for disease treatment 
Microorganisms, including bacteria, viruses and various unicellular or multicellular 
eukaryotes, can live in human body and profoundly influence human health, either 
beneficial (e.g. through vitamin synthesis) or detrimental (e.g. by provoking diarrhea). 
Microbes have long been consumed in a variety of fermented food and drinks to the benefit 
of the host32. With increasing knowledge of human diseases and regulatory roles played by 
microbes in human health, novel living organisms have been generated that can be used 
therapeutically to combat human diseases. Development of the synthetic biology has further 
augmented the power of such living organisms as therapeutic agents, as it enables the 
controlled engineering of the living organisms33. 
Over the past decades, bacteria have also been harnessed to combat cancer. Many 
genera of bacteria have been shown to preferentially accumulate in tumors, including 
Salmonella, Escherichia, Clostridium and Bifidobacterium. Caulobacter, Listeria, Proteus and 
Streptococcu, that all have been investigated as potential anticancer agents34. Numerous 
bacterial strategies have been carried out in pre-clinical and clinical studies. Success has 
been observed in reducing tumor volume and increased survival. Comparing to standard 
cancer therapy, genetic modified bacteria holds advantages of specifically targeting tumors, 
intratumoral penetration, enhanced effectiveness by expressing anticancer agents35. With 
rapid development in this field, there is little standardization before it can be used in the 
clinic. Thus, I engaged to perform a thorough study of the literature to investigate the steps 
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needed to move forward in these respects, especially with the aim of defining novel therapy 
for gastrointestinal and hepatic cancers. 
7. Aims of this thesis 
Prompted by the considerations mentioned above, in this thesis I endeavor to link biology to 
clinical treatment for better therapy of liver cancer and also gastrointestinal cancer. My 
strategy is to increase understanding the molecular mechanisms of HCC development and 
see how these findings can relate to the potential efficacy and of existing medication, 
preferably those already approved for clinical use, as introduction of such medication for 
clinical testing is relatively straightforward. As it is not always possible to target cancer 
biology with existing medication, or that side effects of targeting specific targets in cancer 
biology may well be unacceptable (telomerase comes in mind) I decided also perform an 
exploratory analysis of potential of targeting treatment using genetically modified bacteria. 
To this end, I first explore the use of targeting liver cancer metabolism using purine synthesis 
inhibitors (Chapter 2). These inhibitors are already used for HCC patients in the context of 
immunosuppression following orthotopic liver transplantation, although most patients 
currently receive alternative medication for this purpose. As I now find that these inhibitors 
inhibit the cancer process – while I also characterize their effects on the hepatocyte 
cytoskeleton in detail – my findings imply that the use of such inhibitors for HCC-related 
organ transplantation would be associated with superior clinical outcome. 
The insights gained from the first two chapters set the stage for an in depth analysis 
of the role of IMPDH isoforms in liver cancer cell biology. This analysis is provided in Chapter 
3. As was also observed in chapter 4 (in which differential effects of u-STAT1 and p-STAT1 
will be described) we see that despite the promising results obtained in chapter 2, different 
isoforms of IMPDH have dichotomal effects. Thus the conclusion is that fundamental new 
approaches will be necessary and the remaining part of my thesis explores such approaches. 
Subsequently I focus on STAT1 (Chapter 4). Recently inhibitors that impair STAT1 
phosphorylation have become available in the clinic (e.g. Tofacitinib), while IFNs (that 
stimulate STAT1 phosphorylation) have already been available for clinical use for several 
decades. Improved insight into the relative contribution of phosphorylated and 
unphosphorylated STAT1 may thus help tinkering novel therapy and hence I characterize the 
effects involved and this should prove instrumental in designing rational therapy. 
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In Chapter 5 I characterize the effects of targeting telomerase for anticancer therapy. 
Use of telomerase inhibitors is being impeded by fears of unacceptable side effects on stem 
cell compartments. I actually show, however, that such compartment are quite telomerase 
inhibition resistant. Nevertheless, concerns remain over potential side effects of such 
therapy. 
In chapter 6  I subsequently perform an exploratory analysis on the potential use of 
genetically-modified bacteria to target human disease. Advantages of such a strategy would 
be targeted delivery, with relatively little exposure of other parts of the body to the 
therapeutic proteins involved. I conclude that it might be possible to execute therapy in this 
fashion. 
Chapter 7 provides a discussion and integration of the results obtained: while I 
observe that the increased knowledge on the action of pharmacological compounds 
certainly has implications for our thinking on cancer therapy, cancer cell biology is complex 
and many of the effects observed have relatively little impact and can be considered 
incremental rather as paradigm changing. This is not true for the approach involving 
genetically-modified organisms, however, application of this technology is still in its infancy. 
Hence I am forced to include that despite now millennia of efforts in combating cancer by 
human kind, the battle is far from won and further research remains essential. I delineate 
potential avenues for such research. 
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Abstract 
Tumor recurrence is a major complication following liver transplantation (LT) as treatment 
for hepatocellular carcinoma (HCC). Immunosuppression is an important risk factor for HCC 
recurrence, but conceivably may depend on the type of immunosuppressive medication. 
Mycophenolic acid (MPA) is a currently widely used immunosuppressant acting through 
depletion of guanine nucleotide pools by targeting inosine monophosphate dehydrogenase 
(IMPDH). With clinically achievable concentrations, we found that MPA effectively constrains 
HCC developmentin in both experimental HCC models and HCC-related LT patients. 
Mechanistically, MPA effectively elicited cell cycle arrest and enforced its main target 
IMPDH2 to form rod and ring structures in HCC cells. Most importantly, the use of MMF in 
patients with HCC-related LT was significantly associated with less tumor recurrence and 
improved patient survival. Thus, MPA can specifically counteract HCC growth in vitro and 
tumor recurrence in LT patients involves induction of IMPDH ultrastructural distribution. 
These results warrant prospective clinical trials into the role of MPA-mediated 
immunosuppression following LT of patients with HCC. 
 
Keywords: Liver transplantation (LT), Hepatocellular carcinoma (HCC), Inosine 
monophosphate dehydrogenase 2 (IMPDH2) 
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Introduction 
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide1. 
Surgical resection or liver transplantation (LT) is currently the only potentially curative 
treatment options. LT is particularly attractive because of the radical resection of the tumor 
achieved. Moreover, LT cures the underlying liver disease along with the replacement of the 
diseased liver that remains at risk for the development of new malignant lesions when 
simple tumor resection is executed. However, tumor recurrence is a common threat for the 
success of both surgical resection and LT2. A unique risk factor strongly associated with 
recurrence in LT patients is the universal use of immunosuppressants after transplantation, 
which is to prevent graft rejection3-5 but concomitantly hampers anti-cancer 
immunosurveillance. 
Importantly, immunosuppression involves inhibition of immune cell proliferation and 
thus such therapy might have direct effects on the cancerous compartment as well. Besides 
a general impairment of the immunosurveillance system, different types of 
immunosuppressant could thus directly affect the malignancy process independent of the 
host immunity4, 6-8. Current research efforts in this respect are mainly focused on the 
mammalian target of rapamycin (mTOR) inhibitors, including rapamycin (sirolimus) and 
everolimus9. They are thought to be the only class of immunosuppressive agents that may 
reduce HCC recurrence, and this notion is supported by several retrospective and meta-
analysis studies10-12. However, these studies do not provide firm evidence to establish 
superiority of mTOR inhibitors on HCC recurrence in comparison to other types of 
immunosuppression13. In a recent prospective study, it has been shown that sirolimus in LT 
recipients with HCC does not improve long-term recurrence-free survival beyond five years, 
although a beneficial effect between 3 to 5 years after transplantation in subgroups was 
suggested14, 15. Furthermore, higher rejection rates were reported for monotherapy of 
sirolimus or everolimus in HCC patients with liver transplantation16, 17. The differential 
effects of mTOR inhibitors in patients is probably related to the heterogenicity of HCC18, 19. It 
is unlikely that one immunosuppression protocol fits all cases. Therefore, the impact of other 
immunosuppressants also deserves to be carefully investigated, in order to define 
appropriate immunosuppressive regimens for management of HCC recurrence after LT. 
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Mycophenolic acid (MPA) and its prodrug, mycophenolate mofetil (MMF), are 
currently widely used for prevention of allograft rejection because of lacking 
nephrotoxicity20. These drugs act through depletion of guanine nucleotide pools by 
inhibition of inosine monophosphate dehydrogenase (IMPDH), in particular the isoform 2 
(IMPDH2)21. This results in blockage of de novo guanine nucleotide synthesis and inhibition 
of lymphocyte proliferation20. Interestingly, MPA has been reported to be able to inhibit 
cancer cell proliferation in several experimental models of human solid tumors and 
hematological malignancies22-25. A large prospectively observational cohort study observed a 
tendency towards a lower risk of malignancy in MMF versus non-MMF treated renal 
transplanted patients26. However, this class of immunosuppressant has not been extensively 
studied in the setting of HCC recurrence after LT. This consideration inspired us to explore 
the effects and mechanism-of-action of MPA in experimental HCC models and in HCC-related 
LT patients.  
Patients, materials and methods 
Patient information 
A LT database established in our previous study5 was used for retrospective analysis of the 
effect of MMF on HCC recurrence. This cohort included patients transplanted between 
October 1986 to December 2007 at the Erasmus Medical Centre, Rotterdam, The 
Netherlands. All patients declared that they did not object to the use of their data in the 
study. Retrospective analysis of clinical data was performed in accordance with the approval 
and guidelines of the Medical Ethical Committee of the Erasmus Medical Center. From this 
database 44 out of 385 LT patients were identified as HCC-related LT and thus subjected to 
the analysis in this study. Their clinical information was described in Table S1. 
Reagents 
Stocks of MPA (AMRESCO LLC, USA) were dissolved in dimethyl sulfoxide (DMSO). The final 
concentrations of DMSO were ≤ 0.1%. 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide (MTT) was purchased from Sigma-Aldrich. Matrigel was purchased from BD 
Bioscience. For the cytokines, B27 and N2 were purchased from Invitrogen; N-acetylcysteine, 
gastrin and nicotinamide were purchased from Sigma-Aldrich; EGF, FGF10 and HGF were 
purchased from Peprotech Company. 
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Cell culture 
HCC cell lines, including HuH6, HuH7 and PLC/PFR/5 were grown in Dulbecco’s modified 
Eagle’s medium (DMEM) (GIBCO Life Technologies), supplemented with 10% (v/v) fetal 
bovine serum (FBS) (Hyclone Technologies), 100 units/mL of penicillin and 100 µg/mL of 
streptomycin. All the cells were incubated at 37°C in a humidified atmosphere containing 5% 
CO2. For the control groups in this study, equal volumes of PBS containing the same 
concentration of DMSO as in the drugs were added, which were also marked as MPA at the 
concentration of 0 μM. 
Tumor organoids culture  
Single cells were isolated from liver tumor tissues of mice by using digestion solution as our 
previous study27, 28. Cells were mixed with matrigel, and then were planted into 24-well 
plates in a 37°C incubator for 30 min. After matrigel forming a solid gel, medium was added 
softly. Advanced DMEM/F12 (Invitrogen) works as the basic culture medium, supplemented 
with B27, N2, N-acetylcysteine, gastrin, nicotinamide, EGF, FGF10, HGF and R-spondin1 
(produced by 293T-H-RspoI-Fc cell line). During the first 3 days, Noggin and Wnt3a 
(produced by 293T-HA-Noggin and L-Wnt3a cell lines respectively) were added. The medium 
was replaced every 3 days and passage was performed according to the growth of 
organoids. 
MTT and Alamar Blue assays 
Cells were seeded in 96-well plates, at a concentration of 6×103 cells/well in 100 μL medium. 
All cells were incubated overnight to attach to the bottom of the wells, and then treated 
with serials dilutions of MPA (3, 15, 30 and 60 μM). Cell viability was analyzed by adding 5 
mg/mL MTT and then 150 μL DMSO per well. Absorbance was determined by using a 
spectrophotometric plate reader (Enzyme mark instrument, CytoFluor® Series 4000, 
Perseptive Biosystems) at the wavelength of 490 nm. 
Organoids were split in the ratio of 1:10 for daily culture and seeded in 24-well plates. 
MPA (3 μΜ and 15 μM) was added to the organoids from the initial day. At the third day, 
organoids were incubated with Alamar Blue (Invitrogen, 1:20 in DMEM) for four hours, and 
medium was collected for analysis of the metabolic activity of the organoids. Absorbance 
was determined by using a fluorescence plate reader (CytoFluor® Series 4000, Perseptive 
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Biosystems) at the excitation of 530/25 nm and emission of 590/35 nm. Each treatment 
condition was repeated for three times and matrigel only was used as blank control. 
Colony formation assay 
Cells were harvested and suspended in medium, then seeded into 6-well plates (1000 
cells/well). Formed colonies were fixed by 70% ethanol and counterstained with hematoxylin 
& eosin after two weeks. Colony numbers were counted.  
For single organoid formation, organoids were digested into single cells firstly, and then 
the single living cells were further isolated by FACS sorter (AriaTM, BD Biosciences). 
Propidium iodide (PI) staining was performed to exclude dead cells. Single cells were mixed 
with matrigel and seeded in 24-well plates (100 cells/well) for organoids initiation. Single 
organoids were formed after 5 days, and the sizes and numbers of the organoids were 
calculated. 
Analysis of cell cycle 
Cells (5×105/well) were plated in 6-well plates and incubated overnight to attach the bottom, 
and then serials concentrations of MPA were added. After 48 hrs, control and treated cells 
were trypsinized and washed with PBS and then fixed in cold 70% ethanol overnight at 4°C. 
The cells were washed twice with PBS and incubated with 20 μg/mL RNaseA at 37°C for 30 
mins, and then with 50 μg/mL propidium iodide (PI) at 4°C for 30 mins. The samples were 
analyzed immediately by FACS Calibur. Cell cycle was analyzed by using Flowjo 7.6 software.  
T cell isolation and [3H]-Thymidine assay 
Peripheral blood mononuclear cells (PBMC) were isolated by density gradient centrifugation 
using Ficoll-PaqueTM (Life technologies). T cells were isolated with the Pan T cell isolation kit 
(Miltenyi Biotec) according to the manufacturer’s instructions. Dynabeads coated with 
human T-activator CD3/CD28 antibodies (Life technologies) were added at a cell: bead ratio 
of 20: 1 T cells/well to stimulate T cell expansion and activation. T cells were cultured in 
round-bottom 96-well plates at the concentration of 1×105 cells/well in 200 µL RPMI1640 
medium (GIBCO Life Technologies) supplemented with 10% FCS, at 37°C, 5% CO2, with or 
without compounds. After 3 days, T cell proliferation was assessed by determination of [3H]-
Thymidine (Radiochemical Central, Little Chalfont, UK) incorporation, 0.5 µCi/well was added 
and cultures were harvested 18 hours later.  
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Immunofluorescence assay 
To observe the location and morphology of IMPDH2 protein, Huh7 cells treated with MPA 
were fixed with 4% (w/v) paraformaldehyde (PFA) for 10-15 min at RT. After three washes 
with PBS, cells were permeabilized with 0.1% (v/v) Triton X-100 for 10 min and washed with 
PBS for three times. Subsequently IMPDH2 antibody was used as primary antibody (1:200), 
and anti-rabbit-Alexa Fluor 488-conjuated antibody (1:1000, Cell Signaling Technology) was 
used as secondary antibody for staining. The cells were viewed under the LSM 510 confocal 
microscope (Zeiss, Jena, Germany). The images were analyzed by LSM Image Browser 
software. 
Statistical analysis  
Statistical analysis was performed by using Chi-Square test, nonparametric Mann–Whitney 
test, Cox regression analysis and Kaplan Meier survival analysis in IBM SPSS Statistical 
program (IBM Corporation, Armonk, NY, USA). Mann-Whitney U-test and T-test were 
performed by using GraphPad InStat software (Graph Pad Software Inc, San Diego, USA). P-
values < 0.05 were considered as statistically significant. 
Results 
Use of MMF is associated with reduced HCC recurrence and improved survival  
We investigated the effect of MPA on the outcome of LT patients indicated by HCC in a 
prospectively collected LT cohort5. We have identified 44 out of 385 patients with HCC-
related LT. Twelve cases of these HCC patients were treated with immunosuppressive 
regimens containing MMF at any time during the follow-up and for any period; whereas 32 
patients were treated with immunosuppressive regimens that did not contain MMF. There 
were no significant differences between these groups regarding patient characteristics, 
including age and sex, and regarding known prognostic factors of HCC recurrence after LT29, 
including the size of tumor, the number of lesions, tumor differentiation stage, vascular 
invasion, the level of α-fetoprotein (AFP) before transplantation and time of follow up (Table 
1). 
However, only one out of twelve patients (8.3%) in the MMF group developed 
recurrence; whereas fifteen out of thirty-two patients (46.9%) in the control group 
developed recurrence during follow-up. One patient died in MMF group (8.3%), but eighteen 
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Table 1. Patient characteristics according to MMF use 
No Characteristics MMF use 
No (%/Median)      Yes (%/Median)       
P-valuea 
1 Age 54.94 56.33 ------ 
2 Sex (% male) 23/32 (71.9%) 10/12(83.3%)  0.446 
3 Recurrence* 15/32 (46.9%) 1/12 (8.3%) 0.017* 
4 Death** 18/32 (56.3%) 1/12 (8.3%) 0.004** 
5 Size of tumor (>= 2 cm) b 18/32 (56.2%) 8/12 (66.7%) 0.542 
6 Number of lesions (>= 2) 20/31 (64.5%) 8/12 (66.7%) 0.898 
7 Differentiation 
Good 
Moderate-Bad 
 
9/31 (29.0%) 
22/31 (71.0%) 
 
3/11 (27.3%)        
8/11 (72.7%) 
 
0.798 
0.789 
8 Vaso - invasion 9/30 (30%) 1/11 (9.1%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                  0.176
9 AFP (>25 µg/L) pre-
transplantation 
11/20 (55%) 4/12 (33%) 0.248 
a Categorized parameter were compared using Pearson’s Chi-Square test, mean differences were 
tested using Mann Whitney test. 
b According to the Milan criteria, single lesion <= 5 cm or up to three individual lesions with none 
larger than 3 cm. 
 
Figure 1. MMF use is significantly associated with better clinical outcome in HCC-related LT 
patients. Kaplan Meier analysis (n = 44) revealed that patients using MMF display significantly longer 
times to HCC recurrence (*P ≤ 0.05) (A) and have a better survival (*P < 0.05) (B); Consistently, Cox 
regression analysis showed that patients using MMF have a lower risk of fast recurrence 
(progression) (C) and lower risk of poor survival (*P < 0.05) (D). HR: Hazard Ratio. 
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patients died (56.3%) in the control group. Thus, the use of MMF was significantly associated 
with lower recurrence rates (P < 0.05; Table 1) and higher survival rates (P < 0.01; Table 1). 
Kaplan Meier analysis confirmed that patients using MMF have significantly delayed HCC 
recurrence  (P ≤ 0.05; Figure 1A) and associated with better patient survival (P < 0.05; Figure 
1B). Consistently, Cox regression analysis revealed that patients using MMF have a lower risk 
of fast recurrence (progression; HR = 0.169, 95% CI: 0.022-1.284; Figure 1C) and lower risk of 
demise (HR = 0.128, 95% CI: 0.017-0.967; Figure 1D). These results indicate that MMF use is 
associated with reduced HCC recurrence and improved survival in liver transplant patients.  
MPA inhibited cell proliferation and colony unit formation of human HCC cells  
In order to investigate whether MPA may directly affect the cellular physiology of HCC cells, 
the effects on cell proliferation and single cell colony unit formation (CFU) were evaluated in 
different HCC cell lines. Treatment of MPA inhibits cell proliferation in HuH6, HuH7 and 
PLC/PRF/5 cell lines at clinically relevant concentrations (P < 0.001; Figure 2A). In liver 
transplantation patients, MPA serum peak levels range from 2 to 30 μM, and the drug levels 
in liver will exceed those observed in serum due to accumulation30, 31. Sorafenib, the FDA-
approved anti-HCC drug, is a small inhibitor of several tyrosine protein kinases, including 
VEGFR, PDGFR and Raf family kinases32. The potency of MPA was comparable to Sorafenib, 
in particular at the concentration of 3 μM, although weaker than Sorafenib at a higher 
concentration of 15 μM (P < 0.01; Figure S1A and S1B). Surprisingly, the widely used mTOR 
inhibitor, Rapamycin, did not show inhibitory effect on HCC cells in our experimental setting 
at clinically relevant or even higher concentrations (Figure S1C)33. 
In apparent agreement, MPA profoundly inhibited the number of colonies formed in 
the CFU assay. It appears that even at a relatively low concentration of 3 μM, MPA already 
impeded colony formation (Figure 2B and C). HuH7 cells were more sensitive to MPA 
treatment compared to HuH6 and PLC/PRF/5 cells. In this cell model, 105.70 ± 13.90 colonies 
were formed in untreated cultures but only 13.60 ± 11.25 colonies were formed in 15 μM 
MPA treated group (mean ± SEM, n = 10, P < 0.001; Figure 2C). We concluded that MPA 
strongly interferes with HCC cell expansion in vitro. 
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Figure 2. MPA inhibits cell growth in HCC cell lines. (A) With clinically achievable concentrations, 
MPA potently inhibited cell proliferation, determined by MTT assay (mean ± SEM, n = 6, ***P < 
0.001); (B) and (C) MPA inhibited the ability of colony formation in HuH6, HuH7 and PLC/PFR/5 cell 
lines respectively. (mean ± SEM, n = 9 or 10, respectively, ***P < 0.001). Shown is results from at 
least 3 independent experiments. 
MPA effectively inhibited the initiation and growth of mouse liver tumor 
organoids 
3D culture of primary tumor organoids has been recently demonstrated as advanced liver 
cancer models27, 28, 34. Therefore, we have investigated the effects of MPA on the initiation 
and growth of tumor organoids derived from primary mouse liver tumors. MPA effectively 
inhibited the growth of formed organoids shown by morphological appearance (Figure 3A). 
Alamar Blue assay demonstrated 79.03% ± 0.01 and 82.75% ± 0.01 inhibition at 3 μM and 15 
μM, respectively (mean ± SEM, n = 3, P < 0.001; Figure 3B). Furthermore, MPA robustly 
inhibited the initiation of organoids from the dissociated single organoid cells (Figure 3C). 
The numbers of initiated organoids were 27.67 ± 4.51, 8 ± 1.00 and 4.67 ± 1.70 at 0, 3, and 
15 μM of MPA, respectively (mean ± SEM, n = 3, P < 0.001; Figure 3D). The size of formed 
organoids was inhibited by 82.00% ± 0.08 and 89.09% ± 0.06 at 3 μM and 15 μM of MPA, 
respectively (mean ± SEM, n = 9, P < 0.001; Figure 3E).  
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Figure 3. MPA inhibits the initiation and growth of organoids established from mouse primary liver 
tumors. (A) The appearance of organoids under 3-day MPA treatment; (B) MPA treatment 
significantly inhibited the growth of organoids, as determined by Alamar Blue assays after 3 days 
(mean ± SEM, n = 3, ***P < 0.001); (C) The appearance of single organoids expansion under 5-day 
MPA treatment; (D) The number of organoids (mean ± SEM, n = 3, **P < 0.01). (E) The size of 
organoids after 5 days (mean ± SEM, n = 3, ***P < 0.001). Shown is results from at least 3 
independent experiment. 
The cell cycling of HCC cells was arrested at S-phase by MPA treatment  
To further understand how MPA acts on HCC cell growth, an assay for quantifying cell cycling 
was performed in HuH7 cells. Treatment of MPA dose-dependently increased the proportion 
of S phase by 25.83% ± 0.20 and 131.42% ± 0.32 at the concentrations of 3 and 15 μM, 
respectively. This concomitantly decreased the proportion of cells in the G2/M phase by 
67.82% ± 0.23 and 87.28% ± 0.09 at the concentrations of 3 and 15 μM, respectively (mean ± 
SEM, n = 3, P < 0.05; Figure 4). These data suggested that MPA inhibits HCC cell growth by 
arresting the cell cycle.  
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Figure 4. MPA arrests cell cycling. (A) HuH7 cells were arrested in the S phase by MPA treatment 
(FACS analysis); (B) Quantification of cell cycling analysis (mean ± SEM, n = 3. *P < 0.05; **P < 0.01).  
Exogenous nucleotide supplementation partially counteracts the anti-growth 
effect of MPA  
Depletion of intracellular nucleotide pool is the key immunosuppressive mechanism 
employed by MPA to inhibit lymphocytes proliferation. Supplementation of exogenous 
guanosine nucleotide indeed partially counteracted the anti-proliferative effects of MPA on 
HCC cell lines, but this effect is related to the cell type and dosage (Figure 5A). This effect 
was also observed in colony formation assay. The numbers of colonies were 102.17 ± 19.63, 
31.17 ± 14.02 and 107.67 ± 27.73 in HuH6, HuH7 and PLC/PRF/5 cell lines with MPA (3 μM) 
treatment, respectively. Supplementation of exogenous guanosine nucleotide (25 μM) 
increased the colony numbers to 134.83 ± 29.49, 71.50 ± 9.95 and 145.67 ± 28.91 in HuH6, 
HuH7 and PLC/PRF/5 cell lines, respectively (mean ± SEM, n = 6, P < 0.05 or P < 0.001; Figure 
5B and C). However, high doses of MPA out-compete exogenous guanosine nucleotides, 
especially in HuH7 and PLC/PRF/5 cells (Figure 5A, B and C). 
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Figure 5. Guanosine supplementation partially counteracts effects of MPA. MTT assay of HuH7, 
HuH6 and PLC/PFR/5 cell lines (A) and CFU assay of HuH6 and PLC/PRF/5 cell lines treated with MPA 
or/and guanosine (B) showed that exogenous guanosine could partially counteracted the effect of 
MPA; (C) Quantification of CFU assay (mean ± SEM, n = 6, ***P < 0.005). Shown is results from at 
least 3 independent experiments. 
New IMPDH inhibitors have potential immunosuppressive and/or anti-HCC 
properties  
We explored the possibility to develop new IMPDH inhibitors exhibiting superior anti-HCC 
activity as compared to MPA but with comparable immunosuppressive activity, which may 
constitute improved treatment choices following HCC-indicated LT. Twenty-three IMPDH 
inhibitors were developed and profiled. Their immunosuppressive capability was evaluated 
in a T cell proliferation assay. Fifteen of them were more potent than MPA in inhibiting T cell 
proliferation after 72 h treatment (mean ± SEM, n = 9, P < 0.01; Figure 6A). Intriguingly, four 
out of these compounds (1351, 1353, 1382 and 1407) were identified as more potent 
inhibitors of HuH6 cells proliferation than MPA (mean ± SEM, n = 9, P < 0.05; Figure 6B). 
Collectively, three compounds (1351, 1353 and 1382) were found possessing both stronger 
MPA constrains HCC 
37 
immunosuppressive and anti-tumor activity (Figure 6C). Interestingly, three compounds 
significantly inhibit HuH6 cells proliferation (1393, 1400 and 1407) (compounds vs CTR, mean 
± SEM, n = 9, P < 0.001) without affecting T cell growth (Figure 6C), which suggests that these 
compounds may have potential as new generation of anti-HCC drugs in a non-transplant 
setting that does not require immunosuppression. 
 
Figure 6. Other IMPDH inhibitors and their immunosuppressive and anti-HCC activity. (A) [3H]-
Thymidine assay showed that fifteen compounds were more potent than MPA in inhibiting T cell 
proliferation (mean ± SEM, n = 3, **P < 0.01); (B) MTT assay showed that four compounds were more 
potent than MPA in inhibiting HuH6 cells proliferation (mean ± SEM, n = 3, *P < 0.05); (C) Three 
compounds were verified to be more potent in inhibiting T cells and HuH6 cells than MPA (mean ± 
SEM, n = 3, **P < 0.01). Three compounds could inhibit HuH6 cells proliferation without effecting T 
cell proliferation (compounds vs CTR, mean ± SEM, n = 3, ***P < 0.001). Shown is results from at 
least 3 independent experiments. 
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Cytoplasmic rods and rings in mycophenolic acid treatment 
It has recently been proposed that anti-viral action of ribavarin (RBV) relates to RBV-induced 
rearrangement of IMPDH to form rods and rings35. To obtain further insight whether also the 
anti-oncogenic action of the IMPDH inhibitor MPA has a similar association to altered IMPDH 
ultrastructural distribution, we investigated the effects of the drug of subcellular distribution 
of IMPDH. Interestingly, we observed that MPA exposure can potently induce the 
cytoplasmic rearrangement of IMPDH to form ring and rod-like structures in human 
hepatoma cells, and this could not be completely reversed by guanosine supplementation 
(Figure 7). These observations suggest that the induction of stable ring and rod structures is 
a common action of IMPDH inhibitors, which correlates with the general clinical effects of 
these compounds. 
 
Figure 7. MPA treatment induces RR structure in the human hepatoma Huh7 cells. (A) The IMPDH 
protein shows a dispersed distribution in the cytoplasm of Huh7 cells; (B) After MPA treatment at the 
concentration of 3 µM for 24 hrs, IMPDH was aggregated into RR structure; (C) Supplementation of 
guanosine (25 µM) was unable to reverse MPA-induced IMPDH aggregations. Blue: DAPI nuclear 
staining. Green: antibody against Human IMPDH2.  
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Discussion 
Although it is suspected that immunosuppressive medication following LT facilitates HCC 
recurrence, the issue of how specific immunosuppressive drugs affect the disease process is 
poorly understood36. Obviously, a regimen that can perform its immunosuppressive function 
which is necessary for preventing graft rejection but that concomitantly exerts anti-tumor 
effects should be the preferential clinical choice in this particular setting. In this aspect, 
mTOR inhibitors attract attention. However, only approximately 50% of all HCC patients 
exhibit activation of mTOR downstream signaling elements in their tumors10, 37. Indeed, both 
experimental and clinical evidence suggest that tumors bearing different genetic mutations 
can respond differentially to mTOR inhibitors38, 39. Given the heterogeneity of HCC, other 
immunosuppressive regimens also deserve careful attention. Several studies have reported 
that MPA could inhibit cancer cell proliferation across different types of cancer cell lines40-43 
as well as potentially supportive evidence from patients44, 45.  
In this study, we have demonstrated an anti-cancer effect of MPA in experimental 
HCC models including human HCC cell lines and mouse primary liver tumor organoids. 
Culture of primary liver cancer cells from either human or mouse has been proven to be very 
difficult. The organoid technology (culturing “mini-organ” in 3D) has endowed the possibility 
of establishing stable cultures from primary tumors, including for liver tumors27, 28, 34. Our 
data support that MPA has potent inhibitory effects on HCC growth in vitro. More 
importantly, clear inhibition of mouse liver tumor organoids initiation and growth were also 
observed after MPA treatment. We further provided clinical evidence that the use of MMF, 
the prodrug that metabolizes into MPA after administration, is associated with reduced 
disease recurrence and improved survival in HCC-related liver transplant patients. These 
results indicated an anti-tumor action of MPA occurring.  
Although the anti-tumor effects of MPA have been substantially established, it is still 
unclear how this drug exerts the anti-tumor activity. Several molecular pathways appear to 
play a pivotal role in MPA-induced apoptosis46. Two p53 induced genes (TP53I3 and 
TP53INP1), as well as the p53 protein, are known to be up-regulated by MPA46. The increase 
of p53 level provides a mechanism for rapid growth arrest or apoptosis in the event of DNA 
damage during S phase of cell cycle47. In our study, the induction of S phase arrest in HCC 
cells by MPA is in agreement with these known findings. We surprisingly found that 
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supplementation of exogenous guanosine counteracts only to a minor extent to the 
inhibitory effect of MPA in HCC cells. Although depletion of guanine nucleotide pools by 
inhibiting IMPDHs is the predominate mechanism in inhibiting lymphocyte proliferation, this 
however only partially explain the mechanism-of-action in anti-HCC by MPA.  
Although the exact mechanism by which MPA acts remains unclear, Covini et al. has 
proposed a scenario in which enzymatic activity of IMPDH is shuttled down as a 
consequence of ring and rod formation, which in turn provokes IMPDH to become 
autoantigenic, and hence the production of specific autoantibodies35. This was also found in 
our study during MPA treatment, which induce the ring and rod formation. Thus, targeting 
IMPDH is expected to inhibit cancer by simultaneously blocking nucleotide synthesis and 
provoking immune response through RR structure induced autoantibodies. We think this is 
particularly relevant to therapeutic targeting IMPDH in cancer treatment. The IMPDH2 
isoform is upregulated in a wide range of cancer tissues, associated with disease 
aggressiveness, and related to poor patient survival6. Of note, a general feature of many 
IMPDH inhibitors (e.g. MPA) is immunosuppressive. Therefore, the development of new 
inhibitors retaining the potent antiviral and anti-cancer effects but avoiding 
immunosuppressive activity represents as a new direction to move forward. 
Excitingly, after performing a retrospective analysis in our LT cohort, we found an 
association between MMF use and reduced HCC recurrence and improved patient survival. 
Importantly, there are no significant differences regarding patient and tumor 
characteristics29 between these two groups. It must be said that our observations may also 
be related to a potential inferior immunosuppressive effect of MMF containing treatment 
regimens. Because of the small sample size, the single center setting, and the retrospective 
nature of these findings, further clinical evaluation is warranted preferentially in randomized 
studies to confirm our findings. Moreover, three out of twenty-three other IMPDH inhibitors 
were found to possess both stronger immunosuppressive and anti-tumor activity than MPA 
and may therefore be considered as potential alternatives for MMF in the LT set. 
In summary, this study has demonstrated that clinically relevant concentrations of 
MPA are capable of constraining HCC cell growth in experimental models. We further 
provided clinical evidence that MMF is associated with reduced HCC recurrence and 
improved survival in liver transplant patients. Confirming these experimental findings and 
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retrospective clinical observations by prospective randomized trials could lead to better 
management of immunosuppressive medication for HCC patients after LT.  
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Supplementary Information 
Supplementary Table S1. Clinical information of patients using MMF 
 
No Age 
(yrs) 
LTx date Start date 
MMF 
End date 
MMF 
MMF 
Period 
(weeks) 
Recurrence 
date 
Death  
date 
1 58 22-May-1992 26-Jan-1998 21-Feb-2008 525 - - 
2 50 18-Jan-1998 26-Sep-2002 04-Feb-2011 436 - - 
3 55 18-May-2006 24-May-2006 04-Jul-2013 371 - - 
4 53 28-Jul-2007 13-Aug-2007 12-Jun-2013 304 - - 
5 60 21-Dec-2005 25-Jan-2006 07-May-2009 171 - - 
6 69 21-May-2000 19-Dec-2005 22-Sep-2008 144 - - 
7 63 05-Sep-2007 11-Sep-2007 15-Jun-2010 144 - - 
8 65 20-Nov-2004 15-Sep-2005 17-Mar-2008 130 19-Jun-2007 18-Mar-2009 
9 58 01-Jan-2007 29-Jan-2007 21-Jan-2010 155 - - 
10 24 09-Feb-2005 02-Mar-2005 20-Apr-2006 59 - - 
11 65 23-Aug-2007 23-Aug-2007 21-Sep-2007 4 - - 
12 56 22-Jan-2007 26-Jan-2007 15-Oct-2007 37 - - 
13 52 27-Mar-2007 - - - - - 
14 50 07-Nov-1997 - - - - 18-Jan-2001 
15 52 19-Jul-1997 - - - - 09-Dec-2003 
16 43 02-Mar-1998 - - - - 12-Feb-2000 
17 55 10-Sep-2004 - - - - 23-Aug-2005 
18 60 16-Feb-2000 - - - - - 
19 54 22-Mar-2002 - - - - 11-Jan-2004 
20 63 25-Jan-1994 - - - - 09-Jun-1996 
21 67 26-Jul-1998 - - - - - 
22 56 25-Apr-2005 - - - - 31-Mar-2007 
23 42 31-Mar-2005 - - - - 23-Feb-2006 
24 61 10-Oct-2006 - - - - - 
25 69 05-Apr-2000 - - - - 23-Feb-2001 
26 55 04-Jul-1995 - - - - 13-Sep-1998 
27 58 24-May-2006 - - - - - 
28 24 04-Oct-1989 - - - - 02-Dec-1990 
29 67 04-Mar-2007 - - - - - 
30 64 17-Sep-2007 - - - - - 
31 53 15-Feb-2001 - - - - 21-May-2002 
32 50 03-May-2000 - - - - - 
33 60 17-Oct-1999 - - - - 05-Dec-2008 
34 66 06-Aug-2001 - - - - 22-Jul-2004 
35 48 08-Jul-2004 - - - - - 
36 53 05-Jan-1990 - - - - 26-Jul-1992 
37 46 14-Apr-2004 - - - - 17-Sep-2005 
38 44 01-May-1996 - - - - 30-Aug-1996 
39 61 10-Oct-1999 - - - - - 
40 58 16-Nov-2002 - - - - - 
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41 57 29-Nov-2003 - - - - - 
42 57 17-Oct-1996 - - - - 10-Jul-2000 
43 57 12-Jun-2002 - - - - - 
44 66 15-Mar-2007 - - - - - 
 
Note: - no recurrence/no death/no MMF treatment 
 
Supplementary Figure 1 
 
 
Figure S1. The effects of MPA, Sorafenib and Rapamycin on HCC cell lines. (A) At the low 
concentration of 3 μM, the inhibitory effects of MPA and Sorafenib have no significant 
difference, while at the concentration of 15 μM, Sorafenib* showed more potent effect in 
HuH6 cell line; (B) At the low concentration of 3 μM, MPA has stronger inhibitory effect, 
while at the concentration of 15 μM, Sorafenib showed more potent inhibition in HuH7 cell 
line; (C) The effects of Rapamycin (at the concentrations of 1ng/ml, 10ng/ml and 100ng/ml, 
respectively ) were not significant in HuH6 cell line, determined by MTT assay. (mean ± SEM, 
n = 3, respectively, **P < 0.01, ***P < 0.001).  
*Clinical use of sorafenib is 400 mg twice daily, and the Ctrough sorafenib average 
concentration in patients treated with the dose of 400 mg is 8.78 ± 4.82 μg/ml (equivalent to 
13.78 ± 7.57 μM) 
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Abstract 
Interferons (IFNs) with antiviral and immune-stimulatory functions have been widely used in 
prevention and treatment of hepatocellular carcinoma (HCC). Signal transducer and 
activator of transcription 1 (STAT1) is a key element of the IFN signaling, and the function of 
STAT1 is critically determined by its phosphorylation state. This study aims to understand 
the dynamics and functions of phosphorylated (p-) and unphosphorylated (u-) STAT1 in HCC. 
We found that u-STAT1 is significantly elevated in patient HCC tumor tissues and 
predominantly expressed in cytoplasm; while p-STAT1 is absent. Loss of u-STAT1 potently 
arrested cell cycle and inhibited cell growth in HCC cells. Induction of p-STAT1 by IFN-α 
treatment effectively triggers the expression of interferon-stimulated genes (ISGs), but has 
moderate effect on HCC cell growth. Interestingly, both u-STAT1 and p-STAT1 are induced by 
IFN-α, though with distinct dynamics. Importantly, artificial blocking the induction of u-
STAT1, but not p-STAT1, sensitizes HCC cells to IFN-α treatment. Therefore, p-STAT1 and u-
STAT1 exert opposite functions and coordinately regulate the responsiveness to IFN 
treatment in HCC.  
 
Keywords: Hepatocellular carcinoma (HCC), Signal transducer and activator of transcription 
1 (STAT1), Interferon (IFN) signaling, Immune response 
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Introduction 
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors1 and the 
second leading cause of cancer related-death worldwide2. As a major etiology, chronic 
infection with hepatitis B or C virus (HBV or HCV) triggers liver fibrosis, cirrhosis, and 
eventually the development of HCC3. To prevent from or treat for viral hepatitis-related HCC, 
interferons (IFNs) have been explored in clinic4, 5. In context of tumors, IFNs can be produced 
by various cell types, including immune cells, as well as tumor cells. They elicit antitumor 
effects by directly controlling tumor cells or indirectly by regulating immune response6. 
However, the exact mechanisms remain poorly understood due to their multitude functions 
in respect to both intra-tumoral and micro-environmental determinants7. Although benefits 
of reducing cancer risk have been observed in clinical studies5, IFN treatment for the 
management of HCC is still controversial and no clear recommendations have been 
proposed7.  
Signal transducer and activator of transcription 1 (STAT1), an important upstream 
regulator of the IFN signaling, functions as the core transcription factor to drive the 
transcription of a subset of IFN-regulated genes (IRGs)8. Upon IFN stimulation, phospho-
STAT1 (p-STAT1) acts as a key element for STAT1 homodimerization (STAT1-STAT1) or 
heterodimerization (STAT1-STAT2-IRF9 complex, ISGF3). These complexes translocate to the 
nuclear with subsequent binding to Interferon-Stimulated Response Elements (ISRE) and 
Interferon-Gamma Activated Sequences (GAS), and then stimulate the transcription of IRGs 
to regulate host immune response and cell growth9. Although STAT1 has been found to be 
deregulated in a variety of cancers, the exact role of STAT1 in cancer, especially in different 
types of cells, remains controversial. On one hand, STAT1 is recognized as a tumor 
suppressor which can inhibit tumor growth through regulating cell proliferation, 
differentiation and death10-13. On the other hand, STAT1 can also be a tumor promoter as it 
can promote tumor cell growth, therapy resistance, and immune suppression14, 15. In 
addition, expression of STAT1 has been found to correlate with both good or poor prognosis 
in different types of cancers16. Although STAT1 was reported to be a potential suppressor in 
HCC17, the findings are based on limited numbers of patients and a modest effect on HCC cell 
growth. 
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Upon IFN stimulation, p-STAT1 and unphospho-STAT1 (u-STAT1) act as two forms of 
STAT1 to perform its function18. Although p-STAT1 is recognized as the key activator of IFN 
signaling, u-STAT1 can also regulate gene transcription in the absence of IFN stimulation19. 
Thus, p-STAT1 and u-STAT1 stimulate transcription of different subsets of genes, which have  
distinct functions in immune responses of tumors to IFN-related therapy7. ISGs selectively 
controlled by u-STAT1, denoted as IFN-related DNA damage resistance signature (IRDS), 
have been identified in patients resistant to radio- and chemotherapy. Therefore, p-STAT1 
and u-STAT1 were thought to have distinct functions and have been used as independent 
prognostic markers in predicting disease outcomes in cancer20. 
In this study, we investigated the expression and functions of p-STAT1 and u-STAT1 in 
HCC. Remarkably, we found that STAT1 was predominantly present as u-STAT1 form and was 
highly expressed in the cytoplasm of tumor cells from HCC patients. Although p-STAT1 
induced by IFN-α treatment robustly stimulated ISG expression by activating the IFN 
signaling pathway and inhibited HCC growth, its function was quickly blocked by intrinsic or 
induced u-STAT1. Thus, the tumor suppressive or promoting role of STAT1 largely depends 
on its phosphorylation status. The dynamic induction of p-STAT1 and u-STAT1 by IFN 
treatment coordinately regulates the growth of tumor cells. 
Material and Methods 
Tissue microarray (TMA) 
Archived formalin fixed paraffin-embedded tissue samples from 133 patients who 
underwent hepatic resection for HCC at Erasmus MC-University Medical Center between 
2004 and 2014, were used for this study. Clinical data of this HCC cohort have been 
published previously21. The use of patient materials was approved by the medical ethical 
committee of Erasmus MC. TMA slides contained three or four 0.6 mm cores from the 
tumorous area and two 0.6 mm cores from the paired tumor-free liver (TFL) area of these 
patients. 
Immunohistochemistry 
Paraffin-embedded TMA slides were deparaffinized with xylene and rehydrated in graded 
alcohols (100%, 95%, 70%) for further immunohistochemistry staining. Slides were then 
washed with Phosphate Buffered Saline with Tween 20 (PBST) and boiled in citric acid buffer 
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(pH6.0) for 20 min for antigen retrieval. Peroxidase was blocked by adding 3% H2O2 for 10 
min at room temperature. The slides were incubated overnight with the primary antibody 
against STAT1 (rabbit polyclonal; sc-592) (1:300) and p-STAT1 (58D6; rabbit monoclonal; 
#9176) (1:150) at 4°C. After being rinsed in PBST, slides were incubated with second anti-
rabbit IgG antibody conjugated with HRP for 1 h at room temperature. DAB solution (0.05% 
DAB, 0.0017% H2O2) was then prepared and added to the slides to visualize antibody 
binding. The reaction was stopped by washing with distilled water. Subsequently, 
hematoxylin were employed for background staining of tissue. Negative control staining was 
carried out by omitting the primary antibody. 
Cytoplasmic and nuclear staining were scored separately. Percentages of cells with 
cytoplasmic or nuclear expression were scored as follows: low for 0-30%; moderate for 30-
70%; high for > 70%. Scoring of expression intensity was performed as: grade 1 for weak; 
grade 2 for moderate; grade 3 for strong. A final immune-reactivity score (IRS) was obtained 
for each case by multiplying the percentage and the intensity values, ranging from low, 
moderate and high. The scorings were done by two investigators. 
Colony formation assay 
Cells were trypsinized, harvested and suspended in culture medium. After quantified 
through counting, 2 × 103 cells were seeded into 6-well plates and the medium was 
refreshed for every four days. After two weeks culture, formed colonies were washed with 
PBS and fixed by 70% ethanol. Followed by counterstaining with crystal violet and washed 
with PBS, colony sizes were measured microscopically through digital image analysis. 
MTT assay 
Cells were trypsinized and seeded in a 96-well plate at a concentration of 1 × 103 cells/well. 
After overnight incubation, cells were treated with IFN-α (1000, 5000, 10000 IU/ml) for one 
week and the medium was refreshed for one time. Cell viability was analyzed by incubating 
cells with 0.5 mg/ml MTT (Sigma-Aldrich) for 4 h. After discarding the cell supernatant, 150 
µl DMSO was added followed 10 min shaking. The absorbance was determined using 
enzyme mark instrument at the wavelength of 490 nm. 
 
Dichotomal function of p- and u-STAT1 in HCC 
55 
Cell cycle analysis  
Cells (5 × 105/well) were plated in six-well plates and allowed to attach overnight. When the 
cell confluence reached 60% to 80%, cells were trypsinized and washed with PBS for two 
times and then fixed in cold 70% ethanol overnight at 4°C. The cells were then washed twice 
with PBS and incubated with 50 µl RNase (100 μg/ml ) at 37°C for 30 min, and then 250 µl 
propidium iodide (PI) (50 μg/ml) was added and cells were incubated at room temperature 
for 5 min. The samples were analyzed immediately by FACS. Cell cycle was analyzed by 
FlowJo software. 
Cell apoptosis analysis 
Cell apoptosis analysis was performed by staining cells with annexin V-FITC (BD Pharmingen) 
and PI. Cells (5 × 105/well) were seeded into six-well plates and incubated at 37°C in 5% CO2 
overnight, then cells were treated with IFN-α (Thermo Scientific, the Netherlands) (1000 
IU/ml), TNF-α (Peprotech, USA) (20 ng/ml) or the combination. After 72 h, all of the cells 
were trypsinized and resuspended in annexin-binding buffer (BD Pharmingen) and stained 
with Alexa Fluor 488 Annexin V and PI at room temperature for 15 min. Detection of 
apoptosis was performed by FACS and the results were analyzed by FlowJo software. 
Statistical analysis 
Statistical analysis was performed by using the nonparametric Mann–Whitney test for paired 
or non-paired data, or the paired t test using GraphPad InStat software as appropriate. 
Crude (non-adjustment) survival analysis (Kaplan-Meier curve) was first used to display the 
overall survival difference. Hazard ratio (HRs) and 95% Cls were calculated to evaluate the 
prognostic power of variables of patients. P-value < 0.05 was considered statistically 
significant. 
Results 
STAT1 expression is elevated in tumor tissues of HCC patients 
In order to investigate STAT1 expression in HCC patients, we first searched the online 
datasets from Oncomine and TCGA, including six cohorts of 912 HCC tumor tissues with 834 
paired tumor-free liver tissues from the same patients. To our surprise, STAT1 mRNA 
expression was significantly upregulated in tumors of five of the six cohorts (Figure. 1A-C). 
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To further confirm these results, TMA slides including tumor tissues and paired tumor-free 
liver tissues of 133 HCC patients were stained for STAT1. Positive staining of STAT1 in both 
nuclear and cytoplasm was found in most of the patients. Nuclear STAT1 is often recognized  
 
Figure 1. STAT1 expression is upregulated in tumors of HCC patients. a The Oncomine microarray 
database (https://www.oncomine.org) was searched to analyze mRNA expression of STAT1 in HCC 
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patients. In total, five cohorts of 424 HCC tumor tissues compared with 346 paired tumor-free tissues 
from the same patients were identified. STAT1 mRNA was significantly upregulated in tumors tissues 
compared with tumor-free tissues in  four of the five cohorts, P<0.001. b STAT1 expression profile 
across 488 HCC tumors and paired tumor-free liver tissues derived from TCGA 
(https://cancergenome.nih.gov/). STAT1 mRNA expression was significantly higher in tumor tissues 
comparing with tumor-free tissues (mean ± SD, n=488, ***P<0.001). c Landscape of all the online 
cohorts. d Cytoplasmic STAT1 was significantly upregulated in HCC tumors. The cytoplasmic STAT1 
protein immune-reactivity scores (IRS), obtained by multiplying the scores for proportions of stained 
cells and the scores for expression intensity, range from low (score: 0-3), moderate (score: 3-6), high 
(score: 6-9) (mean ± SEM, n=133, **P<0.01). d No significant difference was found in nuclear STAT1 
expression IRS scores (mean ± SEM, n=133, ns, no significant). 
as p-STAT1, while cytoplasmic STAT1 is referred as u-STAT122. Therefore, we scored the 
nuclear and cytoplasm expression of STAT1 separately. Consistent with the RNA expression 
data derived from the online datasets, cytoplasmic STAT1 protein expression in tumor 
tissues was significantly higher than that in tumor-free tissues (Figure. 1D), but no difference 
in nuclear STAT1 expression between tumors and tumor-free tissues was found (Figure. 1E).  
Among all the clinical factors, alpha-fetoprotein (AFP) serum level and tumor 
differentiation were significantly associated with higher patient mortality (Table. S2). This 
result is consistent with the general consensus that serum AFP is an independent indicator 
for HCC prognosis23. Correlation of STAT1 expression with clinical behavior were further 
analyzed. High cytoplasmic STAT1 was not significantly associated with the analyzed factors 
(Table. S3). However, high nuclear STAT1 expression was significantly associated with patient 
age (Table. S4). Furthermore, no significant correlation was observed between STAT1 
expression and patient survival outcome (Figure. S1). Collectively, we found that cytoplasmic 
STAT1 expression in tumor tissues appears higher compared to tumor-free tissues. 
P-STAT1 is absent in tumor tissues of HCC patients and human hepatoma cell 
lines  
As the key component of JAK-STAT signaling, STAT1 is phosphorylated after activation and 
then translocates to the nucleus. Although u-STAT1 has been generally recognized as 
present in cytoplasm, emerging evidence has indicated its translocation to nuclei and its 
function as a transcription factor24. 
To clarify the phosphorylation status and localization of STAT1, we stained TMA slides 
with tissues of 32 patients with a specific antibodies against phosphorylated STAT1. Hela 
cells treated with IFNs were used as a positive control. Surprisingly, we did not observe 
positive staining for p-STAT1 in both tumor or tumor-free tissues (Figure. 2A). Consistently, 
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p-STAT1 was absent in all HCC cell lines, whereas u-STAT1 was highly expressed (Figure. 2B). 
Thus, we have demonstrated that STAT1 is predominantly present in unphosphorylated 
state in HCC tissues and human hepatoma cell lines. 
 
Figure 2. P-STAT1 is absent in both HCC tumors and cell lines. a No expression of p-STAT1 in HCC 
tumors and tumor-free tissues. Tumors (n=32) and tumor-free tissues (n=19) were stained for p-
STAT1 (Y701). Paraffin-embedded Hela cells treated with IFNs were used as a positive control. b 
Absence of p-STAT1 in HCC cell lines. Cell lysates were collected for Western blot, and qRT-PCR was 
used to measure the mRNA levels of STAT1 (mean ± SD, n=3 independent experiments, two 
biological repeats for each). 
Knockout of u-STAT1 impairs HCC cell growth  
To determine the functions of u-STAT1, we generated u-STAT1 knockout cells by Lenti-
CRISPR/Cas9 system in Huh7 and Huh6 HCC cell lines. Complete loss of STAT1 was 
demonstrated at protein level by western blot analysis (Figure. 3A). Finally, three wild-type 
and three knockout clones of both cell lines were selected for subsequent experimentation. 
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The colony formation unit (CFU) assay measures the ability of single cells to form clones. 
Strikingly, we observed that knockout of u-STAT1 inhibited CFU formation of HCC cells 
(Figure 3B), in contrast to previous findings that STAT1 served as a tumor suppressor17, 20. 
Cell cycle analysis revealed that loss of u-STAT1 significantly increased the proportion of 
Huh7 and Huh6 cells in the G1 phase and concomitantly decreased the proportion of cells in 
S-phase (Figure. 3C). These data suggest that u-STAT1 sustains HCC cell growth by promoting 
cell cycling. 
 
Figure 3. Knockout of u-STAT1 inhibits HCC cell growth. a Knockout of STAT1 in HCC cell lines. Cell 
lysates from Huh7 and Huh6 clones transduced with LentiCRISPR/Cas9 vector were collected for 
western blot. β-actin served as loading control. b U-STAT1 knockout significant inhibited the colony 
formation of Huh7 and Huh6 cell lines, as measured by clone size (mean ± SD, n=27, ***P<0.001, 
**P<0.01). c U-STAT1 knockout arrested cell cycling. U-STAT1 knockout arrested Huh7 and Huh6 cells 
in G1 phase determined by flow cytometric analysis (mean ± SD, n=9. **P<0.01). 
Chapter 4 
60 
Activation of STAT1 phosphorylation by IFN-α treatment hardly inhibits HCC 
cell growth 
As the active form of STAT1, p-STAT1 has been widely recognized as the functional form in 
inhibiting tumor growth through inducing cell apoptosis and arresting cell cycle. Because p-
STAT1 is absent in HCC cells, IFN-α was employed to activate STAT1 phosphorylation. Upon 
 
Figure 4. IFN-α exerts modest inhibition on HCC cells independent of p-STAT1. a IFN-α treatment 
did not or only modestly inhibit HCC cell growth independent of p-STAT1. Huh7 and Huh6 cells were 
treated by IFN-α (1000, 5000 and 10000 IU/ml) for 7 days and cell growth was determined by MTT 
assay (mean ± SD, n=4). P-STAT1 was measured by western blot and was strongly stimulated by 
treatment of IFN-α (1000 IU/ml) for 30 min. b IFN-α (1000 IU/ml) modestly inhibited the colony 
formation. Clone size of IFN-α untreated HCC cells were normalized to treated cells and data were 
present as STAT1 KO cells comparing with controls (CTR) (mean ± SD, n=3, ns, no significant). 
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IFN-α treatment, p-STAT1 was strongly induced in Huh7 and Huh6 cells, but not in STAT1 
knockout cells (Figure. 4A). Huh7 and Huh6 with or without STAT1 were treated with differnt  
 
Figure 5. STAT1 is the key component for IFN-α induced ISG expression but not for cell apoptosis. a 
STAT1 knockout abolished the induction of ISGs by IFN-α. Huh6 KO and Huh7 KO cells were treated 
with IFN-α (1000 IU/ml) for 24 h. ISG expression was determined by qRT-PCR (mean ± SD, n=3, two 
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biological replicates for each independent experiment, *P<0.05, **P<0.01, ***P<0.001 ). b-c p-STAT1 
strongly induced the expression of different ISGs. Huh6 and huh7 cells were treated with IFN-α for 
4h. ISGs were quantified by qRT-PCR (mean ± SD, n=4, *P<0.05, **P<0.01, ***P<0.001). c-d U-STAT1 
regulates IRDS genes but not pro-apoptotic ISGs. The expression of ISGs was compared between 
control and knockout cells in huh6 and huh7 by qRT-PCR (mean ± SD, n=4, *P<0.05, **P<0.01, 
***P<0.001). f HCC cell lines are resistant to apoptosis induction by treatment of IFN-α. Huh6 KO and 
Huh7 KO cells were treated with IFN-α (1000 IU/ml), TNF-α (20 ng/ml) or the combination for 72 h. 
Cells were collected and stained with Anexin V/PI, and subsequently analyzed by FACS (mean ± SD, 
n≥4, *P<0.05, ns, no significant ). 
concentrations of IFN-α. Surprisingly, both cells lines were resistant to IFN-α treatment on 
cell proliferation, although Huh7 cells showed modest growth inhibition. Furthermore, no 
significant difference of cell growth between STAT1 knockout cells and WT controls was 
observed (Figure. 4A). Consistent to the MTT results, only Huh7 cells showed a slight 
inhibition on colony formation and no difference was found between knockout and WT cells 
in both cell lines (Figure. 4B).  
Induction of ISGs is the hallmark of STAT1 activation25. They are thought to be the 
anti-tumor effectors of IFN-α treatment26. As expected, a subset of ISGs were strongly 
induced by IFN-α treatment; while the stimulation was abolished in STAT1 knockout cells 
(Figure. 5A). Besides, p-STAT1 has also been reported as an apoptosis inducer. However, IFN-
α failed to induce apoptosis in HCC cells, while TNF-α did in Huh6 cells (Figure 5B). In 
addition, IFN-α did not further enhance apoptosis in the presence of TNF-α. These results 
suggest that HCC cells are resistant to growth regulation by IFN-α treatment, although p-
STAT1 and ISGs are robustly activated.  
U-STAT1 serves as a feedback loop to block the inhibitory effect of p-STAT1 
on HCC cell growth  
To understand why HCC cells are insensitive to IFN-α treatment, we profiled the dynamics of 
p-STAT1 and u-STAT1 expression. In fact, STAT1 is one of the most important ISGs. Both p-
STAT1 and u-STAT1 were strongly induced by IFN-α. P-STAT1 peaked at 0.5 hour after IFN-α 
treatment and thereafter decreased gradually; whereas u-STAT1 started to gradually 
increase eight hours post-treatment (Figure. 6A). The expression of JAK1 was not changed, 
which has been demonstrated to be inhibited by u-STAT118. We hypothesize that the distinct 
dynamics of these two forms may antagonize each other, and eventually deters the 
response to IFN-α treatment.  
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Figure 6. U-STAT1 works as a feedback loop in blocking p-STAT1 function. a IFN-α treatment 
induced u-STAT1 and p-STAT1 expression. Expression of u-STAT1 and p-STAT1 were both induced in 
Huh7 and Huh6 cells by IFN-α but not in Huh6-KO-WT determined by western blot and qRT-PCR 
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(mean ± SD, n=4, *P<0.05). b Attenuating u-STAT1 expression sensitized Huh6 cell to IFNs treatment. 
Huh6-KO-WT and Huh6-KO-Y701F cells were treated with IFN-α (1000 IU/ml) or IFN-γ (1000 ng/ml). 
Decreased colony formation efficiency was found in Huh6-KO-WT and also cell growth inhibition but 
not in Huh6-KO-Y701F cells determined by MTT assay (mean ± SD, n=3, **P<0.01). c Blocking IFN-α 
induced u-STAT1 expression sensitized HCC cells to apoptosis and cell cycle arrest. Cell lysates of 
Huh6 cells and Huh6-KO-WT treated with IFN-α (1000 IU/ml) or IFN-γ (1000 ng/ml) were collected for 
western blot analysis. β-actin served as loading control. 
To dissect these complicated interactions, we artificially control STAT1 expression by 
genome modification. We exogenously expressed CMV promotor controlled WT (Huh6-KO-
WT) or mutant (Y701F) (Huh6-KO-Y701F) STAT1 in STAT1 knockout Huh6 cells. Thus, STAT1 
mRNA is constitutively expressed driven by the exogenous CMV promoter and therefore no 
longer be induced by IFN-α. Treatment of IFN-α activates p-STAT1, but the expression of u-
STAT1 was not affected in these cells (Figure 6A). As expected, ISG expression was strongly 
induced by IFN-α, although no major effect on the basal expression of ISGs (Figure. S3). 
Importantly, blocking the induction of u-STAT1 expression greatly sensitized Huh6-KO-WT 
cells to IFN-α treatment. In contrast, this effect was not observed in Huh6-KO-Y701F, 
indicating the requirement of p-STAT1 activation (Figure. 6B and 6C). Furthermore, 
exogenous expression of u-STAT1 did not exerted major effect on HCC growth (Figure 6D). 
Cleaved caspase-3 and p21 are the key components of apoptosis and cell cycling. We found 
that both cleaved caspase-3 and p21 expression were stimulated in Huh6-KO-WT cells, but 
decreased in Huh6 cells (Figure. 6E).These results suggest that the induction of u-STAT1 as a 
feedback loop antagonizes the function of p-STAT1 and protects HCC cells from IFN-α 
treatment. 
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Discussion 
As the key component of IFN signaling, STAT1 have been reported with both pro- and anti-
tumor functions during cancer development from clinical studies in cancer patients16. 
Deregulated expression of STAT1 has been observed in a variety of cancer types27-30. It is 
closely correlated to clinical behaviors of patients, either good or poor prognosis14, 29. In HCC, 
the expression of STAT1 has been reported to be lower in tumor tissues and is negatively 
associated with the histological grade17. However, we found that expression of STAT1 is 
higher in HCC tumor tissues in both our patients and other cohorts from online datasets, 
consisting of a large number of patients. Compared to the tumor-free tissues, we found 
higher levels of STAT1 is in the cytoplasm of HCC cells; whereas the levels in nuclear are 
comparable. The exact reasons accounting for the discrepancy between our results and the 
previous studies remain to be further investigated17. 
The phosphorylation status is essential for the functions of STAT1. In general, p-
STAT1 is supposed to locate in nuclear; while u-STAT1 is considered predominately present 
in cytoplasm22. Surprisingly, we found that p-STAT1 is completely absent in our HCC tumor 
tissues and HCC cell lines, indicating that u-STAT1 is the dominant form located in both 
nuclear and cytoplasm. This is consistent with previous finding that u-STAT1 can shuttle 
between cytoplasm and nuclear, and reinforces host defense against viral infection24. 
However, the expression levels of STAT1 in either nuclear or cytoplasm are not significantly 
related to survival in our patients.  
Experimental studies in STAT1 knockout mouse have demonstrated a tumor 
suppressor function mainly through tumor intrinsic and extrinsic mechanisms15, 31. Cell cycle 
regulator, apoptosis inducers and genes of immune system have been recognized as 
downstream targets of STAT1. However, several oncogenes have been reported to be 
regulated by STAT1, which are involved in promotion of tumor growth and invasiveness, 
suppression of immune surveillance and induction of therapy resistance16. Thus, STAT1 plays 
multifaceted roles in cancer development. In HCC, we found that silencing u-STAT1 inhibits 
cell growth and arrests cell cycle, indicating u-STAT1 sustains the growth of HCC. These 
results are partially consistent with previous finding that u-STAT1 can protect tumor cells 
from apoptosis stimuli, radio- and chemotherapy22, 30, 32, 33.  
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The classically active form of STAT1, p-STAT1, is strongly induced during immune 
response and rapidly regulates downstream gene expression. It has been demonstrated that 
p-STAT1 remarkably arrests tumor cell growth34-36. In line with this, we found that p-STAT1 
inhibits HCC cell growth by arresting cell cycle and inducing cell apoptosis. However, p-STAT1 
is quickly dephosphorylated within only a few hours. u-STAT1, which is transcribed by p-
STAT1, subsequently substitutes p-STAT1 expression and lasts for several days. 
Consequently, the anti-tumor effect of p-STAT1 is attenuated by the pro-tumor effect of u-
STAT1. Thus, the function of STAT1 is highly dependent on its phosphorylation state, and p-
STAT1 and u-STAT1 exert opposing functions. 
IFNs have been widely explored for treating various malignancies6. However, IFN 
monotherapy has limited efficacy, although combination of IFNs with other tumoricidal 
therapies have been proven effective37. Systemic thermotherapy with IFNs for HCC has 
limited benefit on patient survival and in some instances is accompanied with significant 
toxicity38, although antiviral therapy with IFNs might reduce the risk of virus infection in 
cancer patients4. Reasons for the clinical failure of IFNs likely include inherent biological 
mechanisms, changes in cell population, and institution of counter-regulatory pathways39. 
IFN signaling is generally considered to stimulate immune response, but it has also been 
reported to induce immunosuppression7. Different forms of STAT1, p-STAT1 and u-STAT1, 
have shown different transcription properties that contribute to the complexity of IFN 
signaling7. In our study, we have demonstrated that p-STAT1 and u-STAT1 have opposing 
functions in HCC during IFN-α treatment. These results may explain the possible mechanisms 
of the ambiguous effects of IFNs in cancer treatment. 
In summary, STAT1 is dominantly present as the form of u-STAT1 in HCC cells. The 
phosphorylation state deters the functions of STAT1 that u-STAT1 sustains but p-STAT1 
inhibits HCC growth. Upon IFN treatment, the expression, phosphorylation and localization 
of STAT1 are dynamically regulated and coordinately control the responsiveness to IFN 
treatment. Thus, these findings provide mechanistic insight on the role of STAT1 in HCC, and 
provide scenario for future optimization of IFN treatment. 
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Supplementary Materials  
Bioinformatics analysis of online datasets  
To analyze mRNA expression of STAT1 in HCC, the Oncomine microarray database 
(https://www.oncomine.org) was analyzed using the online tool. In the Gene Expression 
Omnibus (GEO) database , datasets of HCC gene expression were searched and analyzed 
(accession codes GSE14520). STAT1 mRNA expression was analyzed in identified cohorts by 
comparing expression levels in HCC tumors with tumor-free tissues. Moreover, survival data 
of 360 HCC cases in The Cancer Genome Atlas (TCGA) were available 
(https://portal.gdc.cancer.gov/projects/TCGA-LIHC). 
Immunohistochemistry 
Paraffin-embedded TMA slides were deparaffinized with xylene and rehydrated in graded 
alcohols (100%, 95%, 70%) for further immunohistochemistry staining. Slides were then 
washed with Phosphate Buffered Saline with Tween 20 (PBST) and boiled in citric acid buffer 
(pH6.0) for 20 min for antigen retrieval. Peroxidase was blocked by adding 3% H2O2 for 10 
min at room temperature. The slides were incubated overnight with the primary antibody 
against STAT1 (rabbit polyclonal; sc-592) (1:300) and p-STAT1 (58D6; rabbit monoclonal; 
#9176) (1:150) at 4°C. After being rinsed in PBST, slides were incubated with second anti-
rabbit IgG antibody conjugated with HRP for 1 h at room temperature. DAB solution (0.05% 
DAB, 0.0017% H2O2) was then prepared and added to the slides to visualize antibody 
binding. The reaction was stopped by washing with distilled water. Subsequently, 
hematoxylin were employed for background staining of tissue. Negative control staining was 
carried out by omitting the primary antibody. 
Cytoplasmic and nuclear staining were scored separately. Percentages of cells with 
cytoplasmic or nuclear expression were scored as follows: low for 0-30%; moderate for 30-
70%; high for > 70%. Scoring of expression intensity was performed as: grade 1 for weak; 
grade 2 for moderate; grade 3 for strong. A final immune-reactivity score (IRS) was obtained 
for each case by multiplying the percentage and the intensity values, ranging from low, 
moderate and high. The scorings were done by two investigators. 
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Cell culture and reagents  
Seven different human hepatoma cell lines (Huh7, Huh6, PLC, snu398, snu449, snu182, 
HepG2) were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Lonza). Media were 
supplemented with 10% (v/v), fetal bovine serum (FBS) (Hyclone Technologies), 100 
units/mL of penicillin and 100 μg/mL of streptomycin. All the cells were incubated at 37°C in 
a humidified atmosphere containing 5% CO2. All the cell lines were a kind gift from Dr. Ron 
Smits (department of Gastroenterology and Hepatology, Erasmus MC-University Medical 
Center) [1] and confirmed mycoplasma-free and their STR genotyping was analyzed at the 
Department of Pathology, Erasmus Medical Center Rotterdam. 
Generation of STAT1 knockout cells using LentiCRISPR/Cas9 system 
The sgRNA (TCCCATTACAGGCTCAGTCG) targeting STAT1 was designed by online tool “MIT 
CRISPR Design” (http://crispr.mit.edu/) and cloned into the lentiviral backbone vector 
lentiCRISPR v2 (Addgene). To produce lentivirus, HEK293T cells were transfected with 0.6 µg 
of pMD.2G, 1.5 µg of psPAX2, and 2 µg of lentiCRISPR v2 in a 6-well plate. Lentivirus-
containing culture supernatants were collected and filtered through a 0.45 µm filter. Cells 
were then infected with lentivirus for two days and selected using 3.0 µg/ml puromycin 
(Sigma-Aldrich). From stably transduced cell lines, single cells were sorted by FACS, and 
genomic DNA was isolated using Wizard® Genomic DNA Purification Kit (Promega) to identify 
the introduced mutations (Figure. S2). To further validate the knockout effect, western blot 
was performed to detect the expression of STAT1 at protein level. 
Colony formation assay 
Cells were trypsinized, harvested and suspended in culture medium. After quantified 
through counting, 2 × 103 cells were seeded into 6-well plates and the medium was 
refreshed for every four days. After two weeks culture, formed colonies were washed with 
PBS and fixed by 70% ethanol. Followed by counterstaining with crystal violet and washed 
with PBS, colony sizes were measured microscopically through digital image analysis. 
MTT assay 
Cells were trypsinized and seeded in a 96-well plate at a concentration of 1 × 103 cells/well. 
After overnight incubation, cells were treated with IFN-α (1000, 5000, 10000 IU/ml) for one 
week and the medium was refreshed for one time. Cells were then incubated with 0.5 
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mg/ml MTT (Sigma-Aldrich) for 4 h. After discarding the cell supernatant, 150 µl DMSO was 
added followed 10 min shaking. The absorbance was determined using enzyme mark 
instrument at the wavelength of 490 nm. The formula: (Absorbance treated cells-Absorbance 
DMSO)/(Absorbance negative control-Absorbance DMSO) was used to analyze the cell viability. 
Cell cycle analysis  
Cells (5 × 105/well) were plated in six-well plates and allowed to attach overnight. When the 
cell confluence reached 60% to 80%, cells were trypsinized and washed with PBS for two 
times and then fixed in cold 70% ethanol overnight at 4°C. The cells were then washed twice 
with PBS and incubated with 50 µl RNase (100 μg/ml ) at 37°C for 30 min, and then 250 µl 
propidium iodide (PI) (50 μg/ml) was added and cells were incubated at room temperature 
for 5 min. The samples were analyzed immediately by FACS. Cell cycle was analyzed by 
FlowJo software. 
Cell apoptosis analysis 
Cell apoptosis analysis was performed by staining cells with annexin V-FITC (BD Pharmingen) 
and PI. Cells (5 × 105/well) were seeded into six-well plates and incubated at 37°C in 5% CO2 
overnight, then cells were treated with IFN-α (Thermo Scientific, the Netherlands) (1000 
IU/ml), TNF-α (Peprotech, USA) (20 ng/ml) or the combination. After 72 h, all of the cells 
were trypsinized and resuspended in annexin-binding buffer (BD Pharmingen) and stained 
with Alexa Fluor 488 Annexin V and PI at room temperature for 15 min. Detection of 
apoptosis was performed by FACS and the results were analyzed by FlowJo software. 
Western blot assay 
Laemmli sample buffer containing 0.1 M DTT (freshly made) was used to lyse the cells. Then, 
cell lysates were denaturalized by heating 5-10 min at 95°C followed by loading onto a 10-
15% sodium dodecyl sulfate-polyacrylamide SDS gel and separated by electrophoresis (SDS-
PAGE). After 90 min running in 120 V, proteins were electrophoretically transferred onto a 
polyvinylidene difluoride (PVDF) membrane (Invitrogen) for 1.5 h with an electric current of 
250 mA. Subsequently, the membrane was blocked with blocking buffer (Li-COR, Lincoln, 
USA) mixed with PBST in ratio of 1:1. And then followed by overnight incubation with rabbit 
anti-STAT1, anti-p-STAT1 (Y701) (1:1000) antibody at 4°C. Membrane was washed 3 times 
with PBST, which was followed by incubation for 1 h with anti-rabbit or anti-mouse IRDye-
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conjugated secondary antibodies (Li-COR, Lincoln, USA) (1:5000) at room temperature. Blots 
were assayed for actin content as standardization of sample loading, and scanned and 
quantified by odyssey infrared imaging (Li-COR, Lincoln, USA). The results were analyzed 
with Odyssey 3.0 software. 
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Figure S1. Survival analysis of HCC patients. a Kaplan Meier analysis of HCC patients from 
the TCGA cohort. Expression of STAT1 is not strongly associated with patient outcome (n=360, 
p=0.386). b Kaplan Meier analysis of the EMC patient cohort. Both cytoplasm (n=126, 
p=0.431) and nuclear expression (n=126, p=0.591) were analyzed for patient survival 
outcome. No significant correlation with patient outcome was found. 
 
 
Figure S2. Genome sequencing of STAT1 knockout cell clones. The sequence locus of STAT1, 
red labeled as the sgRNA targeting site and green labeled as the PAM sequence. All the 
clones show frameshift mutation with nucleotides deletion (dash line) or insertion (red). 
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Figure S3. Expression of ISGs are restored by STAT1 overexpression. a STAT1 re-expression 
does not further induce the expression of ISGs (mean ± SD, n=3, two replicates *p<0.05). b 
STAT1 expression restores the function of IFN-α in inducing ISG expression. Huh6 cells 
transduced with lentiviral vector expressing STAT1 were treated with IFN-α for 24 h (mean ± 
SD, n=3, two replicates *p<0.05), NC=negative control (Huh6 transfected with empty lenti-
vector) 
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Figure S4. STAT1 did not promote HCC cell growth Huh6-KO-WT and Huh6-KO-Y701F cells 
were grown for one week. Cell growth was determined by MTT assay (mean ± SD, n=3, two 
biological replicates for each independent experiment). 
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Table S1. Human qPCR primer sequences 
  5' FORWARD 3' REVERSE 
GAPDH GTCTCCTCTGACTTCAACAGCG ACCACCCTGTTGCTGTAGCCAA 
IFIT1 GCCTTGCTGAAGTGTGGAGGAA ATCCAGGCGATAGGCAGAGATC 
IFIT3 CCTGGAATGCTTACGGCAAGCT GAGCATCTGAGAGTCTGCCCAA 
IFI27 CGTCCTCCATAGCAGCCAAGAT ACCCAATGGAGCCCAGGATGAA 
ISG15 CTCTGAGCATCCTGGTGAGGAA AAGGTCAGCCAGAACAGGTCGT 
OAS1 AGGAAAGGTGCTTCCGAGGTAG GGACTGAGGAAGACAACCAGGT 
MX1 GGCTGTTTACCAGACTCCGACA CACAAAGCCTGGCAGCTCTCTA 
IRF1 GAGGAGGTGAAAGACCAGAGCA TAGCATCTCGGCTGGACTTCGA 
STAT1 ATGGCAGTCTGGCGGCTGAATT CCAAACCAGGCTGGCACAATTG 
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Table S2. Patient characteristics according to HCC specific mortality. 
Variable   HR(95%CL) P 
Age  0,735 (0,287-1,884) 0,522 
AFP (>200)*** 6,808 (2,207-16,797) 0,000 
Tumor Size 3,298 (0,967-11,244) 0,057 
Fibrosis   1,341 (0,392-4,582) 0,640 
Cirrhosis  1,238 (0,436-3,516) 0,688 
Vascular invasion 1,524 (0,644-3,604) 0,338 
HBV positive 0,003 (0,000-1,659E+63) 0,941 
HCV positive 0,006 (0,000-3,011E+63) 0,947 
Viral hepatitis  305,841 (0,000-1,505E+68) 0,941 
Differentiation* 0,242 (0,070-0,831) 0,024 
Gender   1,468 (0,590-3,651) 0,409 
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Table S3. Patient characteristics according to cytoplasmic STAT1 expression 
Variable   HR(95%CL) P 
Age 
 
0,981 (0,466-2,068) 0,960 
AFP (>200) 0,959 (0,314-3,006) 0,959 
Tumor Size 1,707 (0,632-4,607) 0,291 
Fibrosis  
 
1,878 (0,543-6,494) 0,319 
Cirrhosis 
 
0,887 (0,371-2,122) 0,788 
Vascular invasion 1,261 (0,576-2,762) 0,561 
HBV positive 0,855 (0,361-2,026) 0,721 
HCV positive 0,422 (0,153-1,167) 0,097 
Differentiation 0,541 (0,191-1,533) 0,248 
Gender   0,850 (0,390-1,852) 0,683 
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Table S4. Patient characteristics according to nuclear STAT1 expression 
Variable   HR(95%CL) P 
Age** 
 
0,372 (0,178-0,778) 0,009 
AFP (>200) 2,401 (0,967-5,964) 0,059 
Tumor Size 0,976 (0,468-2,032) 0,947 
Fibrosis  
 
0,606 (0,202-1,814) 0,371 
Cirrhosis 
 
1,235 (0,510-2,991) 0,640 
Vascular invasion 0,632 (0,303-1,319) 0,222 
HBV positive 0,308 (0,025-3,749) 0,356 
HCV positive 0,602 (0,059-6,142) 0,668 
Viral hepatitis  1,994 (0,156-25,487) 0,595 
Differentiation 2,662 (0,960-7,369) 0,060 
Gender   0,717 (0,363-1,415) 0,338 
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Abstract 
Bacteria have now been harnessed to combat human diseases, especially to meet the 
challenge of antimicrobial resistance. Modulating the microbiome, particularly by genetically 
engineering the bacteria, has provided proof-of-concept as potential pharmacotherapy, but 
this field should engage in discussion as how to move forward. 
Chapter 6 
84 
Over the ages, the rapid and invisible transmission of infectious diseases has inspired shock 
and awe to human society. With the emergence and advent antibiotic medication, fear for at 
least bacterial infection has been substantially subdued. However, rapidly spreading 
antibiotic resistance because of inappropriate use of this class of medications has provided 
new urgency to the quest of developing alternative anti-microbial strategies1. Intriguingly, 
these efforts have led to realization that living organisms can be used therapeutically to 
combat infectious diseases, defining a novel group of therapeutic entities which in turn are 
also used for the treatment of non-infectious diseases. DNA recombinant technology, 
through which bacteria are manipulated to express biomedical molecules ectopically, can 
greatly add to the power of living organisms as therapeutic agents. There is, however, very 
little standardization with respect to mode of delivery, consensus as to measure 
pharmacokinetics of genetically engineered bacteria and the required precautions with 
respect of contamination of ecosystems with genetically modified organisms or the 
transmission of harmful organisms to patients. Thus, the field should engage in discussion as 
how to move forward in these respects. 
Such discussion is especially called for in view of the rapid development in the field. 
Consider for instance, the recent study of Hwang et al. published in Nature Communications 
in which a genetically engineered Escherichia coli Nissle, for preventing and treating 
intestinal Pseudomanas asruginosa infection was described2. In this elegant study, an 
engineered microbe was used that can specifically detect P. aeruginosa-secreted 
autoinducer N-acyl homoserine lactone and subsequently responds to this pathogen by 
inducing its own lysis, thus releasing an anti-P. aeruginosa toxin  and an anti-biofilm enzyme. 
The bacteria establish chronic colonization of the intestine, hence preventing further 
colonization of the pathogen and providing prophylactic activity. These findings open a new 
era in the treatment of antibiotic-resistant infection, especially as it is highly specific to a 
defined pathogen associated with both prevention and treatment to the specific 
microorganism. Concomitantly, new questions emerge with respect how to define, dose and 
measure amounts of this therapeutic organism, and how to assess potential ecological risks 
of such bacteria, following excretion of modified organisms out of the body. 
Some guidance in this respect may be obtained from the experience with probiotics 
and prebiotics. Probiotics are bacterial which naturally occur in fermented foods and drinks 
and are associated with a variety of health benefits, These include protection against 
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pathogenic infection through niche occupation, reduced intestinal inflammation and 
increased Ca++ uptake in the gut. They are used as preventive or supportive medication in a 
variety of conditions such as irritable bowel syndrome, inflammatory bowel disease, 
infectious and antibiotic-related diarrhea, allergy and eczema, oral health as well as certain 
urinary and vaginal health-related conditions3. Prebiotics are dietary fibers that allow 
intestinal expansion of probiotic bacteria4. However, despite the regular use of probiotics 
and prebiotics as medication and functional food, there is still little in guidance as to how 
assess pharmacokinetics of such preparations. This partly relates as to doubts as to their 
clinical efficacy. Although some evidence of clinical effectiveness of probiotics has been 
provided for certain diseases, such as antibiotic-associated diarrhea, Clostridium difficile-
associated colitis, irritable bowel syndrome and inflammatory bowel disease 3, much of the 
data presented in contemporary body of medical literature is inconsistent. Furthermore, 
doubts have been raised with respect to safety of probiotic preparations. The PROPATRIA 
trial (which assessed the clinical efficacy of probiotics in pancreatitis) showed excessive 
mortality to be associated with such treatment5. Given the fact that almost no standard 
quality or content of probiotics has been established, it is imperative that the field develops 
guidelines in this respect.  
A similar situation holds true for fecal microbiota transplantation (FMT). FMT has 
seen an almost stellar increase in popularity for treatment of a variety of gastrointestinal 
and non-gastrointestinal disorders, in particular Clostridium difficile-associated colitis6 but 
also inflammatory bowel disease and metabolic syndrome. In this strategy, feces of healthy 
individuals are used for reestablishing the homeostasis in a dysbiotic human gut, usually by 
delivery through endoscopy7. For Clostridium difficile-associated colitis, an impressive 
efficacy in resolution of infection was observed in over 90% of FMT-treated as compared to 
31% and 23% in conventional antibiotic treatment. Nevertheless, the complex compositions 
of fecal might unavoidably expose patients to undetected organisms or even harmful 
pathogens8; whereas the importance of using living organisms for this treatment has also 
been challenged9. Nevertheless, the approach remains superior relative to the use defined 
consortia of bacteria10 and its popularity raises important question as how to define dosing 
and other pharmacokinetic parameters and prompt further development in this area. 
It is important to point that this field is developing quickly driven by the advances in 
molecular biology. The production of therapeutic proteins through genetically modified 
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organisms at mucosal surfaces has important advantages, in particular the possibility to 
achieve local delivery which increases efficacy and at the same time reduces side effects. 
The successful Phase I clinical trial with interleukin 10-producing Lactococcus lactis for the 
treatment of Crohn’s disease illustrates the promise of such strategies11. Bacteria can be 
manipulated to express a plethora of potentially biomedically interesting molecules, such as 
hormones, interleukins and antibodies. In this way, they can circumvent barriers associated 
with conventional strategies in delivery and production of these proteins and help lowering 
the side effects as well as productions cost12. The field, however, needs to anticipate such 
developments and should pro-actively address questions (Box 1) as to how to define 
pharmacokinetic parameters of therapeutic preparations consisting of living bacteria.  
Box 1. Development and challenges in harnessing living organisms as pharmaceutical 
modality. 
 The use of bacteria for disease prevention or treatment has become clinical reality 
and benefits specificpatients. However, some of the clinical effects appear modest 
and need to be further mechanistically clarified, also in view of that almost no 
standard for quality control of the bacteria has been established. 
 Risks have been raised in treating certain groups of patient. For instance, sepsis 
caused by probiotics (neonates, immunosuppression, pancreatitis) remains a feared 
complication Furthermore, FMT may unavoidably cause the transmission of 
undetected or unknown pathogens. 
 Different strains of bacteria and the aspecific composition of bacteria preparations 
may vary dramatically in their therapeutic efficacy. To define the underlining 
mechanisms will help to provide guidance in treating with particular strains for 
specific diseases. 
 Genetically modified bacteria have shown their advantages in combating diseases in 
some clinical trials, but may hold the risks of contamination of ecosystems and 
transmission between the human beings. Developing biocontainment bacteria with 
resistant to evolutionary escape will greatly meet the future demand in considering 
of bacteria biosafety. 
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Exploring molecular alterations for HCC therapy 
Cancer has now been recognized a specific type of pathology for at all millennia and during 
all this time efforts at treatment have proven frustrating disappointing. For much of the 
time, cancer treatment was hampered by a lack of understanding of the underlying driving 
forces. The advent of nucleotide sequencing technology, however, has allowed analysis of 
the cancer process in unprecedented detail. Overwhelming evidence now shows 
oncogenesis to be cause of genetic mutation and to involve both of gain function changes in 
oncogenes and concomitant loss of function in tumor suppressor genes1. These changes are 
in the vast majority of cases sequential in which succession of the alterations in the genome 
transforms normal cells to cancer cells, while diversity in the gene mutation patterns 
provokes cancer cell heterogeneity, a phenomenon that substantially hampers successful 
treatment2. Efforts to categorize the cancer process and also its diversity in presentation 
have led to of the definition of eight hallmarks of cancer, that in conjunction should provide 
a logical framework describing the disease on a mechanistic level and which I used during my 
thesis research to study the liver cancer problem (see also introduction). Let us here 
summarize as what has been achieved. 
Treatment of HCC is only curative if the primary cancer is physically removed and no 
metastases remain in the body. To achieve this, medical professionals often have to resort to 
liver transplantation. This is obviously a demanding procedure and its consequence if life-
long use of immunosuppressive medicine to prevent rejection of the liver graft. Intriguingly 
this entails possibilities. Graft rejection and cancer share a need for cell division, the former 
to expand the lymphocyte compartment, the latter to expand the tumor compartment. As a 
consequence immunosuppressive medication sometimes shares characteristics with anti-
cancer medication and if liver cancer is particularly sensitive to specific immunosuppressive 
medication, such medication may actually prevent recurrence. This notion is explored in 
Chapter 2, which is the synthesis of two of our separately studies, in which we show that 
IMPDH inhibition not only protects liver grafts but also counteracts the liver cancer process. 
Mechanistically, I could link this process to altered subcellular distribution of the enzyme 
involved. As other medication, e.g. ribavirin, also provokes altered subcellular distribution of 
IMPDH, it should prove interesting to investigate its effects on HCC as well and I feel that 
further studies investigating this possibility are called for. 
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In Chapter 3 and Chapter 4, we aim to investigate the function of STAT1 and IMPDHs in HCC 
progression, which are related to immune response and metabolism of cancer. 
In Chapter 3, we demonstrated that two isoforms of the IMPDH enzyme exert distinct 
functions in HCC. The expression of IMPDH2 is downregulated in HCC tumors and positively 
associated with prognosis of HCC patients. This is unexpected in view of that elevated 
expression of IMPDH2 is associated with aggression of cancer. Intriguingly, in the 
subpopulation of patients in which nuclear localization of IMPDH2 was detected, it was 
significantly associated with longer survival. In contrast, expression of IMPDH1 is significantly 
up-regulated in the tumor tissue, and higher expression is related to better cumulative 
survival. The in vivo and in vitro experiment confirmed that IMPDH1 sustains but IMPDH2 
inhibits the initiation and growth of HCC tumors.  
Elevation of the expression of IMPDH2 across a wide spectrum of cancer types 
suggests that it is an excellent target for anticancer therapy6. However, even if these 
inhibitors exert potent effects on cancer cell growth, their efficacy remains obscure for now7, 
8. With the exploring distinct function of two IMPDH isoforms, I hope I help understanding 
the complexity of the tumor cell in response to IMPDH2 inhibitors. Nevertheless, the 
complexity observed highlights the problems in devising and defining better therapy and 
stress the need for further research. 
IMPDH inhibitors, such as mycophenolic acid (MPA) and its prodrug MMF, have been 
widely used in the clinic for the prevention of allograft rejection in organ recipients. Organ 
transplantation patients are generally at higher risk of developing malignancy9. Prevention of 
tumor recurrence is the major challenge of achieving this goal. With the finding of IMPDH in 
the HCC progression, it would be interesting to evaluate the effect of MMF/MPA treatment 
on HCC recurrence in liver transplantation patients. 
In Chapter 4, I found that expression of STAT1 was higher in tumor tissues and mainly 
presented as u-STAT1, maybe to be expected in the absence of IFN treatment. It is known 
that high p-STAT1 levels following IFN treatment are transient and only last for several 
hours, after which STAT1 mainly is mainly manifest as u-STAT1. Intriguingly, I demonstrated 
the existence of both a nuclear and cytoplasmic u-STAT1 fraction, maybe consistent with a 
previous finding that u-STAT1 can shuttle between the cytoplasm and nucleus. By 
translocating to the nucleus, u-STAT1 can exert a transcription factor function and regulate 
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the expression of a subset of ISGs to aid host defense against viral infection and conceivably 
cancer. However, the spectrum of ISGs apparently regulated by p-STAT1 and u-STAT1 
substantially differes. Some ISGs were found only to be regulated by u-STAT1 but not p-
STAT1. Importantly, previous studies have demonstrated that p-STAT1 can protect tumor 
cells from apoptosis stimuli, radio- and chemotherapy. An implication of my result thus is 
that changing the balance between p-STAT1 and u-STAT1 (in favor of the latter) would in 
increased propensity of the cancer to respond to treatment while simultaneously substantial 
anti-viral activity of the transcription factor would remain. With advent of medication like 
tofacitinib clinically achieving such an effect looks feasible and I feel this possibility should be 
actively investigated. 
Type I IFNs have attracted substantial interest for the treatment of various 
malignancies3. However, most studies show only limited efficacy with respect to tumor 
suppression and much of these effect mainly being related to prevention of virus-related 
cancers, suggesting such effects mainly relate to direct combat of viral infection4, 5. Reasons 
for the clinical failure of IFNs in cancer medicine likely include inherent biological 
mechanisms, changes in cell population, and institution of counter-regulatory pathways. IFN 
signaling is generally considered to stimulate immune response, but it has also been 
reported to induce immunosuppression under specific conditions4. As the key transducer of 
signaling by IFNs, phosphorylation of STAT1 following IFN stimulation is close linked to 
expression of IRGs as also explained above. I speculate that production of designer IFNs and 
their delivery to precancerous lesions in the tract, for instance by genetically modified 
bacteria (see later), would be capable of eliminating these not yet full-blown cancer cells, 
also by altering the balance between u-STAT1 and pSTAT1. Testing such an idea in practice, 
however, is still quite far away. 
Developing novel strategies for anticancer therapy 
With remarkable progress in research on cancer pathogenesis, a myriad of plausible 
therapies has become developed or even introduced into the clinic. Disappointingly, 
however, cancer, however, still ranks as the second leading cause of death worldwide to 
date. Surgery, radiotherapy and chemotherapy remain the main adequate and effective 
modes of treatment and thus curative rates largely dependent on early detection. Limited 
efficacy and unavoidable side effects toward normal cells make the development of new 
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targeting strategies and drugs urgently needed. In Chapter 5 and Chapter 6, I aim to evaluate 
the safety of telomerase targeted anticancer strategy and discuss the application of 
microorganisms for disease treatment. 
Targeting telomerase appears an attractive approach bar the potential side effects on 
stem cell populations which thus may negatively affect medium term health of the patient. 
In Chapter 5 and given that the intestine and liver are at forefront of drug absorption and 
metabolism, it found it essential to understand how adult stem cells in these tissues/organs 
cope with these telomerase-targeted agents. I found that telomerase-targeted agents 
strongly inhibited the HCC and CRC cell growth, while intestinal and liver stem cell were 
relatively tolerant to these agents. Sensitivity of stem cells to telomerase-targeted agents 
also correlated with telomerase activity: intestinal stem cells but not liver stem cell have 
telomerase activity. Adult stem cells are known to be well-equipped to cope with DNA 
damage and also to maintain genetic stability. I found that Wnt signaling, which is important 
for stem cell renewal and tissue regeneration, is also important for tolerance of stem cells to 
telomerase length challenging stimuli. This function was dependent on the regulation of 
different DNA repair genes including TERT. Telomerase is normally absent in quiescent stem 
cells and will be activated during cell division. It seems that Wnt signaling, telomerase 
activity, cell proliferation are concurrent events, and the cooperation of these factors will 
balance the sensitivity and resistance of stem cells to telomerase targeted agents. 
In Chapter 6, I discussed how to use the genetic modified bacteria for disease 
treatment. Despite the advancement in cancer gene therapy, specific and efficient gene 
delivery systems are still lacking. Incomplete tumor targeting, inadequate tissue penetration 
and limited toxicity are three main reasons responsible for the limitations of the cancer 
therapy10, 11. Alternative, genetically engineered bacteria have attracted more attentions and 
being developed as delivery vector for gene therapy. With advanced engineering technology, 
bacteria can be modified into a tiny robot factories with the function of targeting tumors, 
producing cytotoxic molecules, self-propel, response to triggering signaling, sensing local 
environment and producing external detectable signals12. 
Recently, numerous experiments have shown that bacterial therapies can 
successfully regress tumor size and promote cancer survival in mice. Challenges, however, 
remain with respect to limited drug production, intrinsic bacterial toxicity, targeting 
efficiency, genetic instability and combination with other therapies13. Furthermore, there is 
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little standardization, hampering use in the clinic, including in that of the mode of delivery. 
There is also little consensus as hoe to measure pharmacokinetics of genetically engineered 
bacteria, and the required precautions with respect to contamination of ecosystems with 
genetically modified organisms or the transmission of harmful organisms to patients. 
Nevertheless, in view of incremental improvements reached by alternative approaches, also 
due to complexity of the biological systems involved, a radical departure of existing 
approaches is called for, and the use of genetically-modified organisms may offer this. 
Chapter 6 
96 
Conclusions and future perspectives 
 Commonly, gain-of-function mutation in oncogenes and loss-of-function mutations in 
tumor suppressor genes are the essential genetic alterations in cancer development. 
Different post-translational manifestations of gene products, however, will also 
remarkably influence cellular phenotype. This thesis provides important examples of 
this: the phosphorylation state of STAT1 and the different isoforms and subcellular 
localization of IMPDH were associated with distinct or even opposite functionality in 
HCC development. As STAT1 and IMPDH are the targets of clinically approved drugs 
(e.g. IFNs and MPA), this observation will help developing and optimizing drug 
treatment. As a genetic disease, exploring functions of different genes and key 
signaling pathways will largely improve the knowledge of molecular pathogenesis of 
cancer and contribute to the development of new anticancer therapies. 
 Human adult stem cells, such as intestinal and liver stem cells, are remarkably 
tolerant for telomerase-targeting agents. Our study bears important implications for 
advancing the development of telomerase-targeted anticancer therapy, and has 
provided an important example for using human organoid models in the evaluation 
of drug safety, an observation also important in the quest for reduced use of 
experimental animals. Wnt signaling is identified as a signaling module that helps 
coping with DNA damage and is a regulator of TERT expression. In combination with 
the fact that telomerase and Wnt signaling are both needed for the proliferation of 
the stem cells, we speculate that all these factors are concurrent to balance 
sensitiveness and resistance of stem cells to drug treatment. 
 With the various advantages associated with harnessing engineered bacteria for 
disease treatment, the successful use of engineered bacteria for cancer therapy may 
be just over the horizon. Challenges and opportunities are coexist regarding the 
advance in synthetic biology and understanding the host-bacteria interaction, 
however, lacking of the comprehensive test in human and bacteria strains with high 
efficiency, safety and biocontainment. 
Summary and discussion 
97 
References 
1. Stratton MR. Exploring the genomes of cancer cells: progress and promise. Science 
2011;331:1553-8. 
2. Turajlic S, Sottoriva A, Graham T, et al. Resolving genetic heterogeneity in cancer. Nat Rev 
Genet 2019. 
3. Parker BS, Rautela J, Hertzog PJ. Antitumour actions of interferons: implications for cancer 
therapy. Nat Rev Cancer 2016;16:131-44. 
4. Snell LM, McGaha TL, Brooks DG. Type I Interferon in Chronic Virus Infection and Cancer. 
Trends Immunol 2017;38:542-557. 
5. Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 
2016;2:16018. 
6. Hedstrom L. IMP dehydrogenase: structure, mechanism, and inhibition. Chem Rev 
2009;109:2903-28. 
7. Takebe N, Cheng X, Wu S, et al. Phase I clinical trial of the inosine monophosphate 
dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma 
patients. Clin Cancer Res 2004;10:8301-8. 
8. Rodriguez-Pascual J, Sha P, Garcia-Garcia E, et al. A preclinical and clinical study of 
mycophenolate mofetil in pancreatic cancer. Invest New Drugs 2013;31:14-9. 
9. Tjon AS, Sint Nicolaas J, Kwekkeboom J, et al. Increased incidence of early de novo cancer in 
liver graft recipients treated with cyclosporine: an association with C2 monitoring and 
recipient age. Liver Transpl 2010;16:837-46. 
10. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006;6:583-92. 
11. St Jean AT, Zhang M, Forbes NS. Bacterial therapies: completing the cancer treatment 
toolbox. Curr Opin Biotechnol 2008;19:511-7. 
12. Forbes NS. Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer 2010;10:785-
94. 
13. Chien T, Doshi A, Danino T. Advances in bacterial cancer therapies using synthetic biology. 
Curr Opin Syst Biol 2017;5:1-8. 
 
 
 
 
 
 
 
 
  
 
 
  
 
Chapter 8 
 
Nederlandse samenvatting 
Dutch summary 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dutch summary 
101 
Het paraplubegrip kanker is afgeleid van het Latijnse woord "cancer" wat op haar beurt een 
leenvertaling is van het Griekse woord 'karkínos', dat oorspronkelijk "krab" betekende, maar 
door Hippocrates ook werd gebruikt voor gezwellen in het lichaam. Een lichaamsgezwel 
deed Hippocrates denken aan een in het zand ingegraven krab. Woekerende cellen, die 
aanleiding geven tot tumoren en kanker vormen één van de meest hardnekkige 
gezondheidsproblemen en voorzaken onnoemelijk menselijk leed. In dit proefschrift probeer 
ik bij te dragen aan strijd der mensheid tegen deze ziekte. Ik concentreer mij hierbij op 
leverkanker en dikke darmkanker.  
Leverkanker, en met name het hepatocellulair carcinoom (HCC) als oook dikke 
darmkanker zijn kwaadaardige wildgroeisels die ontstaan na genetische beschadigingen van 
de darmcellen dan wel  de levercellen (hepatocyten). Op mondiaal niveau zijn beide vormen 
van zeer veel voorkomend, waaraan jaarlijks vele miljoenen mensen komen te verscheiden. 
In Nederland is HCC relatief zeldzaam, maar is het wel de meest voorkomende vorm van 
primaire kwaadaardige tumoren in de lever. Dit promotieonderzoek is uitgevoerd aan het 
Erasmus Medisch Centrum van de Erasmus Universiteit van Rotterdam, en dit centrum heeft 
van alle Academische Centra in ons land in absolute termen de meeste leverkankerpatiënten 
en het is dus een logische locatie om deze ziekte te gaan onderzoeken. Een uitvoerige 
motivatie en achtergrond voor de gestelde doelen met betrekking ott het in dit proefschrift 
beschreven onderzoek wordt in Hoofdstuk 1 door mij gegeven. 
In Hoofdstuk 2 presenteer ik de synthese van twee gepubliceerde studies waaraan ik 
een belangrijke heb geleverd (Chen K, Sheng J, Ma B, Cao W, Hernanda PY, Liu J, Boor PPC, 
Tjon ASW, Felczak K, Sprengers D, Pankiewicz KW, Metselaar HJ, Ma Z, Kwekkeboom J, 
Peppelenbosch MP, Pan Q. Suppression of Hepatocellular Carcinoma by Mycophenolic Acid 
in Experimental Models and in Patients. Transplantation 2019 May;103(5):929-937 en Chen 
K, Ma B, Peppelenbosch MP, Pan Q. Cytoplasmic rods and rings in mycophenolic acid 
treatment. Liver Int. 2017 Nov;37(11):1742-1743). In dit hoofdstuk presenteer ik 
experimenten dia laat zien dat de immuunsuppressieve medicatie mycofenolzuur de groei 
van HCC remt zowel in proefdieren als in weefselkweken van HCC.  Een belangrijke 
observatie hierbij was dat HCC patiënten die via transplantatie een nieuwe lever kregen en 
ook werden behandeling met het mycofenolzuur kregen, zowel langer niet dood gaan en 
ook minder vaak terugval van de ziekte vertonen wanneer deze werden vergeleken met HCC 
patiënten welke een levertransplantatie ondergingen en therapie kregen met alternatieve 
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immunosuppressiva. Dit effect ging gepaard met specifieke veranderingen in het celskelet. 
Mijn studies wijzen sterk in de richting van dat mycofenolzuur gebruik na transplantatie van 
de lever bij  HCC patiënten een goed idee met betrekking tot behandeling is. 
Een vraag die daarna opborrelde uit de bovengenoemde resultaten, was hoe dan het 
mycofenolzuur een dergelijk effect zou kunnen bewerkstelligen. Het Mycofenolzuur 
interfereert met de werking van twee enzymen welke betrokken zijn bij de zogenaamde 
nucleotidesynthese, namelijk het inosine monophosphate dehydrogenase 1 en het inosine 
monophosphate dehydrogenase 2 (IMPDH1 en IPDMH2). Het is een logische gedachte dat  
dat dan deze twee enzymen ook een rol zouden hebben zijn bij de anti-kanker werking van 
mycofenolzuur. De eerste aanleiding dat deze gedachte inderdaad juist is, kan worden 
gevonden in Hoofdstuk 3.  In dit hoofdstuk presenteer ik data die aantonen dat het specifiek 
blokkeren van IMPDH2 het delen van tumorcellen afremt, wederom zowel in proefdieren 
alsmede in kankerkweekjes. Vooral het snel delende compartiment van HCC is gevoelig voor 
het remmen van IMPDH2, waar het langzaam-groeiende compartiment minder gevoelig 
hiervoor is. Hoewel deze observaties doen veronderstellen dat HCC niet compleet verdwijnt 
na IMPDH2 remming, vormt het tegengaan van snelle HCC groei an sich, al vaak een 
belangrijk doel bij de behandeling van deze ziekte. Daarnaast kan ik mij voorstellen dat door 
het verminderen van de groei van HCC, het immuun-systeem van de HCC patiënt meer tijd 
gegeven wordt om een effectief antwoord tegen het kankerproces te formuleren. Vooral 
omdat, zoals boven reeds gesteld na transplantatie van de lever immuun-suppressie per se 
noodzakelijk blijkt tijdens de behandeling en als gevolg daarvan de patiënten dus een in 
verhouding zwak immuun-systeem hebben, is dit punt niet onbelangrijk.  
In een vierde studie (Hoofdstuk 4), inmiddels reeds gepubliceerd (Ma B, Chen K, Liu P, 
Li M, Liu J, Sideras K, Sprengers D, Biermann K, Wang W, IJzermans JNM, Cao W, 
Kwekkeboom J, Peppelenbosch MP, Pan Q.  Dichotomal functions of phosphorylated and 
unphosphorylated STAT1 in hepatocellular carcinoma. J Mol Med (Berl). 2019 Jan;97(1):77-
88.) kijk ik naar de rol van de zogenaamde STAT eiwitten. Recentelijk zijn middelen die STAT 
eiwitten kunnen remmen op de markt gekomen voor menselijk gebruik. Omgekeerd, kan 
medicatie als interferon juist STAT eiwitten activeren. STATs lenen zich dus goed voor 
therapeutische interventie. Ik kon inderdaad aantonen dat HCC gekarakteriseerd werd door 
de aanwezigheid van meer STAT en geactiveerd en niet geactiveerd verschillende rollen 
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hebben in de lever (kanker) cel. Met behulp van deze informatie is rationeel gebruik van 
STAT modulatoren bij de behandeling van leverkanker dichterbij gekomen.  
Voor mij het belangrijkste hoofdstuk van dit proefschrift is Hoofdstuk 5. In dit 
hoofdstuk ga ik in op telomerase, was ook wel de Achilleshiel van kanker wordt genoemd. 
Telomerase is een enzym dat voorkomt dat het DNA tijdens de celdeling steeds korter 
wordt. Bij elke celdeling wordt in elk chromosoomeinde zo’n 100 nucleotiden korter na zo’n 
50 delingen is de DNA lengte niet meer verenigbaar met celdeling en stop de proliferatie. 
Zowel kankercellen alsook stamcellen hebben echter het enzym telomerase dat het DNA 
weer verlengd tot de oorspronkelijke lengte. Het ligt dus voor de hand om het telomerase 
enzym te remmen bij de behandeling van kanker. Echter, de angst bestaat dat dit ook het 
eind zou betekenen van gezonde stamcelcompartimenten in het lichaam, iets wat 
uiteindelijk onacceptabele bijwerkingen zou opleveren. Ik heb nu gevonden dat stamcellen, 
althans in de lever en de darm, relatief goed telomeraseremming kunnen weerstaan en ook 
de onderliggende moleculaire details opgehelderd, wat de weg opent naar het klinisch 
testen van zulke inhibitoren. 
De laatste studie in dit proefschrift (Hoofdstuk 6) betreft een literatuurstudie naar 
een radicale nieuwe manier om therapeutische eiwitten in het menselijk lichaam te krjgen 
en zelfs louter lokaal hun werk te laten doen zonder systemische (lichaamsbrede) 
bijwerkingen. Het gaat hier om genetisch gemodificeerde bacteriën. Bacteriën zijn goedkoop 
te kweken en vele voelen zich van nature prettig thuis in de darm. Waar therapeutische 
eiwitten normaliter in de darm worden afgebroken, geldt dit niet voor eiwitten die door 
darmbacteriën worden gemaakt. Door bacteriën genetisch te modificeren kunnen deze 
therapeutische eiwitten gaan maken. Mogelijkheden zijn ontstekingsremmende eiwitten 
maar ook eiwitten die preventief zijn met betrekking tot kanker. De haalbaarheid en 
mogelijkheden worden geëxploreerd in dit hoofdstuk, wat ook gepubliceerd werd in een 
toonaangevende tijdschrift (Ma B, Pan Q, Peppelenbosch MP. Genetically Engineered 
Bacteria for Treating Human Disease. Trends Pharmacol Sci. 2017 Sep;38(9):763-764). 
In het laatste hoofdstuk (Hoofdstuk 7) vat ik de kennis samen die ik elders in dit 
proefschrift heb vergaard met betrekking tot lever- en darmcellen en hun relatie tot het 
kankerproces. Ook probeer ik een meer helder beeld te schetsen hoe mogelijke nieuwe 
therapie met als doel het behandelen en zelfs het genezen van HCC, er mogelijk uit zou 
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kunnen komen te zien. Alles tezamen hoop ik met dit proefschrift een aanzet te hebben 
kunnen geven voor zulke nieuwe therapie. 
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